Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
  • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
  • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
  • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
  • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
  • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
  • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
  • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
  • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/515—Complete light chain, i.e. VL + CL
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/52—Constant or Fc region; Isotype
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
  • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
  • C07K2317/565—Complementarity determining region [CDR]
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
  • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2317/00—Immunoglobulins specific features
  • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
  • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K2319/00—Fusion polypeptide
  • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Definitions

• B7-H3 The B7 homology 3 protein (B7-H3) (also known as CD276 and B7RP-2, and referred to herein as "B7-H3”) is a type I transmembrane glycoprotein of the immunoglobulin superfamily. Human B7-H3 contains a putative signal peptide, V-like and C-like Ig domains, a transmembrane region and a cytoplasmic domain.
• B7-H3 isoforms having either a single IgV-IgC-like domain (2IgB7-H3 isoform) or a IgV-IgC-IgV-IgC-like domain (4IgB7-H3 isoform) containing several conserved cysteine residues.
• the predominant B7-H3 isoform in human tissues and cell lines is the 4IgB7-H3 isoform (Steinberger et al, J. Immunol. 172(4): 2352-9 (2004)).
• B7-H3 has been reported as having both co-stimulatory and co-inhibitory signaling functions (see, e.g. , Chapoval et al, Nat. Immunol. 2: 269-74 (2001); Suh et al, Nat. Immunol. 4: 899-906 (2003); Prasad et al, J. Immunol. 173: 2500-6 (2004); and Wang et al, Eur. J. Immunol. 35: 428-38 (2005)).
• B7-H3 co-stimulatory function since B7-H3 was able to increase proliferation of cytotoxic T-lymphocytes (CTLs) and upregulate interferon gamma (IFN- ⁇ ) production in the presence of anti-CD3 antibody to mimic the T cell receptor signal
• CTLs cytotoxic T-lymphocytes
• IFN- ⁇ interferon gamma
• murine B7-H3 has been found to bind to the triggering receptor expressed on myeloid cells (TREM-) like transcript 2 (TLT-2), a modulator of adaptive an innate immunity cellular responses. Binding of murine B7-H3 to TLT-2 on CD8 + T-cells enhances T-cell effector functions such as proliferation, cytotoxicity and cytokine production (Hashiguchi et al., Proc. Nat'l. Acad. Sci. U.S.A. 105(30): 10495-500 (2008)).
• B7-H3 is not constitutively expressed in many immune cells ⁇ e.g., natural killer (NK) cells, T- cells, and antigen-presenting cells (APCs)), however, its expression can be induced. Further, the expression of B7-H3 is not restricted to immune cells.
• B7-H3 transcripts are expressed in a variety of human tissues including colon, heart, liver, placenta, prostate, small intestine, testis, and uterus, as well as osteoblasts, fibroblasts, epithelial cells, and other cells of non-lymphoid lineage, potentially indicating immunological and non-immunological functions (Nygren et al. Front Biosci. 3:989-93 (2011)). However, protein expression in normal tissue is typically maintained at a low level and thus, may be subject to post-transcriptional regulation.
• B7-H3 is also expressed in a variety of human cancers, including prostate cancer, clear cell renal cell carcinoma, glioma, melanoma, lung cancer, non-small cell lung cancer (NSCLC), small cell lung cancer, pancreatic cancer, gastric cancer, acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), ovarian cancer, colorectal cancer, colon cancer, renal cancer, hepatocellular carcinoma, kidney cancer, head and neck cancer, hypopharyngeal squamous cell carcinoma, glioblastoma, neuroblastoma, breast cancer, endometrial cancer, and urothelial cell carcinoma.
• human cancers including prostate cancer, clear cell renal cell carcinoma, glioma, melanoma, lung cancer, non-small cell lung cancer (NSCLC), small cell lung cancer, pancreatic cancer, gastric cancer, acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL),
• B7-H3 Although the role of B7-H3 in cancer cells is unclear, its expression may orchestrate signaling events that may protect cancer cells from innate and adaptive immune responses. For example, B7-H3 is overexpressed in high-grade prostatic intraepithelial neoplasia and adenocarcinomas of the prostate, and high expression levels of B7-H3 in these cancerous cells is associated with an increased risk of cancer progression after surgery (Roth et al. Cancer Res. 67(16): 7893-900 (2007)). Further, tumor B7-H3 expression in NSCLC inversely correlated with the number of tumor-infiltrating lymphocytes and significantly correlated with lymph node metastasis (Sun et al.
• B7-H3 may also play an important role in T-cell-mediated antitumor responses in a context dependent manner.
• gastric cancer tumor cell expression of B7-H3 positively correlated with survival time, infiltration depth, and tissue type (Wu et al., World J. Gastroenterol. 12(3): 457-9 (2006)).
• high expression of B7-H3 in pancreatic tumor cells was associated with patient survival after surgical resection and significantly correlated with the number of tumor-infiltrating CD8 + T-cells (Loos et al, BMC Cancer 9:463 (2009).
• Antibody drug conjugates represent a relatively new class of therapeutics comprising an antibody conjugated to a cytotoxic drug via a chemical linker.
• the therapeutic concept of ADCs is to combine binding capabilities of an antibody with a drug, where the antibody is used to deliver the drug to a tumor cell by means of binding to a target surface antigen, including target surface antigens that are overexpressed in the tumor cells.
• the present invention provides for antibodies and antibody drug conjugates
• ADCs that specifically bind to human B7-H3.
• the present invention provides novel ADCs that can selectively deliver Bcl-xL inhibitors to target cancer cells, e.g., B7-H3 expressing cells.
• the present invention provides an antoi-B7-H3 antibody, or antigen binding portion thereof, that binds to human B7-H3 (hB7-H3), wherein the antibody, or antigen binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 12 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 15.
• the anti-B7-H3 antibody, or antigen binding portion thereof comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 140 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 7.
• the anti-B7-H3 antibody, or antigen binding portion thereof comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 10 and a light chain variable region comprising a CDR1 having the amino acid sequence of either SEQ ID NO: 136 or 138.
• the present invention provides an anti- B7-H3 antibody, or antigen binding portion thereof, that binds to human B7-H3 (hB7-H3), wherein the antibody, or antigen binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 35 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 39.
• the anti-B7-H3 antibody, or antigen binding portion thereof comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 34, and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 38.
• the anti-B7-H3 antibody, or antigen binding portion thereof comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 33 and a light chain variable region comprising a CDR1 having the amino acid sequence of either SEQ ID NO: 37.
• the anti-B7-H3 antibody, or antigen binding portion thereof is an IgG isotype. In one embodiment, the anti-B7-H3 antibody, or antigen binding portion thereof, is an IgGl or an IgG4 isotype.
• the anti-B7-H3 antibody, or antigen binding portion thereof has a K D of 1.5 x 10 8 or less as determined by surface plasmon resonance.
• the present invention provides an anti-B7-H3 antibody, or antigen-binding portion thereof, that binds to hB7-H3, said antibody, or antigen-binding portion thereof, comprising either (i) a heavy chain variable region comprising a CDR set of SEQ ID NOs: 10, 11, and 12, and a light chain variable region comprising a CDR set of SEQ ID NOs: 14, 7, and 15, or (ii) a heavy chain variable region comprising a CDR set of SEQ ID NOs: 33, 34, and 35, and a light chain variable region comprising a CDR set of SEQ ID NOs: 37, 38, and 39.
• the present invention provides an anti-B7-H3 antibodythat binds to human B7- H3 (hB7-H3), wherein the antibody comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 12 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 15.
• the anti-B7-H3 antibody comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 140 and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 7.
• the anti-B7-H3 antibody comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 10 and a light chain variable region comprising a CDR1 having the amino acid sequence of either SEQ ID NO: 136 or 138.
• the present invention provides an anti- B7-H3 antibody that binds to human B7-H3 (hB7-H3), wherein the antibody, or antigen binding portion thereof, comprises a heavy chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 35 and a light chain variable region comprising a CDR3 having the amino acid sequence of SEQ ID NO: 39.
• the anti-B7-H3 antibody comprises a heavy chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 34, and a light chain variable region comprising a CDR2 having the amino acid sequence of SEQ ID NO: 38.
• the anti-B7-H3 antibody comprises a heavy chain variable region comprising a CDR1 having the amino acid sequence of SEQ ID NO: 33 and a light chain variable region comprising a CDR1 having the amino acid sequence of either SEQ ID NO: 37.
• the anti-B7-H3 antibody is an IgG isotype.
• the anti-B7-H3 antibody is an IgGl or an IgG4 isotype.
• the anti-B7-H3 antibody has a K D of 1.5 x 10 8 or less as determined by surface plasmon resonance.
• the present invention provides an anti-B7-H3 antibody that binds to hB7-H3, said antibody comprising either (i) a heavy chain variable region comprising a CDR set of SEQ ID NOs: 10, 11, and 12, and a light chain variable region comprising a CDR set of SEQ ID NOs: 14, 7, and 15, or (ii) a heavy chain variable region comprising a CDR set of SEQ ID NOs: 33, 34, and 35, and a light chain variable region comprising a CDR set of SEQ ID NOs: 37, 38, and 39.
• the anti-B7-H3 antibody, or antigen binding portion thereof is humanized.
• the anti-B7-H3 antibody, or antigen binding portion thereof further comprises a human acceptor framework.
• the human acceptor framework comprises an amino acid sequence selected from the group consisting of SEQ ID Nos: 155,156, 164, 165, 166, and 167.
• the human acceptor framework comprises at least one framework region amino acid substitution.
• the amino acid sequence of the framework is at least 65% identical to the sequence of said human acceptor framework and comprises at least 70 amino acid residues identical to said human acceptor framework.
• the human acceptor framework comprises at least one framework region amino acid substitution at a key residue, said key residue selected from the group consisting of a residue adjacent to a CDR; a glycosylation site residue; a rare residue; a residue capable of interacting with human B7-H3; a residue capable of interacting with a CDR; a canonical residue; a contact residue between heavy chain variable region and light chain variable region; a residue within a Vernier zone; and a residue in a region that overlaps between a Chothia-defined variable heavy chain CDR1 and a Kabat-defined first heavy chain framework.
• the key residue is selected from the group consisting of 48H, 67H, 69H, 71H, 73H, 94H, and 2L.
• the key residue substitution is in the variable heavy chain region and is selected from the group consisting of M48I, V67A, I69L, A71 V, K73R, and R94G.
• the key residue substitution is in the variable light chain region and is I2V.
• the present invention provides an anti-B7-H3 antibody, or antigen-binding portion thereof, that binds to hB7-H3 comprising a heavy chain variable region comprising a CDR set of SEQ ID NOs: 25, 26, and 27, and a light chain variable region comprising a CDR set of SEQ ID NOs: 29, 30, and 31.
• the anti-B7-H3 antibody, or antigen binding portion thereof is humanized.
• the anti-B7-H3 antibody, or antigen binding portion thereof further comprises a human acceptor framework.
• the human acceptor framework comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 155 to 158. In one embodiment, the human acceptor framework comprises at least one framework region amino acid substitution. In one embodiment, the amino acid sequence of the framework is at least 65% identical to the sequence of said human acceptor framework and comprises at least 70 amino acid residues identical to said human acceptor framework. In one embodiment, the amino acid sequence of the framework is at least 85% identical, 90% identical, 95% identical, 96% identical, 97% identical, 98% identical, or 99% identical to the sequence of the human acceptor framework and comprises at least 70, at least 75, at least 80, or at least 85 amino acid residues identical to the human acceptor framework.
• the human acceptor framework comprises at least one framework region amino acid substitution at a key residue, said key residue selected from the group consisting of: a residue adjacent to a CDR; a glycosylation site residue; a rare residue; a residue capable of interacting with human B7-H3; a residue capable of interacting with a CDR; a canonical residue; a contact residue between heavy chain variable region and light chain variable region; a residue within a Vernier zone; and a residue in a region that overlaps between a Chothia-defined variable heavy chain CDRl and a Kabat-defined first heavy chain framework.
• the key residue is selected from the group consisting of 69H, 46L, 47L, 64L, and 71L.
• the key residue substitution is in the variable heavy chain region and is L69I.
• the key residue substitution is in the variable light chain region and is selected from the group consisting of L46P, L47W, G64V, and F71H.
• the present invention provides an anti-hB7-H3 antibody, or antigen-binding portion thereof, comprising a heavy chain CDRl comprising an amino acid sequence as set forth in
• a heavy chain CDR2 comprising an amino acid sequence as set forth in SEQ ID NO: 140
• a heavy chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 12
• a light chain CDRl comprising an amino acid sequence as set forth in SEQ ID NO: 136 or 138
• a light chain CDR2 comprising an amino acid sequence as set forth in SEQ ID NO: 7
• a light chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 15.
• the present invention provides an anti-hB7-H3 antibody, or antigen-binding portion thereof, comprising a heavy chain CDRl comprising an amino acid sequence as set forth in SEQ ID NO: 33, a heavy chain CDR2 comprising an amino acid sequence as set forth in SEQ ID NO: 34, a heavy chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 35, a light chain CDRl comprising an amino acid sequence as set forth in SEQ ID NO: 37, a light chain CDR2 comprising an amino acid sequence as set forth in SEQ ID NO: 38, and a light chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 39.
• the anti-hB7-H3 antibody, or antigen-binding portion thereof comprises a heavy chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 139 and a light chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 135.
• the anti-hB7-H3 antibody, or antigen-binding portion thereof comprises a heavy chain comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 139, and/or a light chain comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 135.
• the anti-hB7-H3 antibody, or antigen-binding portion thereof comprises a heavy chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 139 and a light chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 137.
• the anti-hB7-H3 antibody, or antigen-binding portion thereof comprises a heavy chain comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 139, and/or a light chain comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 137.
• the anti-hB7-H3 antibody, or antigen-binding portion thereof comprises a heavy chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 147 and a light chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 144.
• the anti-hB7-H3 antibody, or antigen-binding portion thereof comprises a heavy chain comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 147, and/or a light chain comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 144.
• the present invention provides an anti-hB7-H3 antibody comprising a heavy chain CDRl comprising an amino acid sequence as set forth in SEQ ID NO: 10, a heavy chain CDR2 comprising an amino acid sequence as set forth in SEQ ID NO: 140, a heavy chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 12, a light chain CDRl comprising an amino acid sequence as set forth in SEQ ID NO: 136 or 138, a light chain CDR2 comprising an amino acid sequence as set forth in SEQ ID NO: 7, and a light chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 15.
• the present invention provides an anti-hB7-H3 antibody comprising a heavy chain CDRl comprising an amino acid sequence as set forth in SEQ ID NO: 33, a heavy chain CDR2 comprising an amino acid sequence as set forth in SEQ ID NO: 34, a heavy chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 35, a light chain CDRl comprising an amino acid sequence as set forth in SEQ ID NO: 37, a light chain CDR2 comprising an amino acid sequence as set forth in SEQ ID NO: 38, and a light chain CDR3 comprising an amino acid sequence as set forth in SEQ ID NO: 39.
• the anti-hB7-H3 antibody comprises a heavy chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 139 and a light chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 135.
• the anti-hB7-H3 antibody comprises a heavy chain comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 139, and/or a light chain comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 135.
• the anti-hB7-H3 antibody comprises a heavy chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 139 and a light chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 137.
• the anti-hB7-H3 antibody comprises a heavy chain comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 139, and/or a light chain comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 137.
• the anti-hB7-H3 antibody comprises a heavy chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 147 and a light chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 144.
• the anti-hB7-H3 antibody comprises a heavy chain comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 147, and/or a light chain comprising an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 144.
• the anti-hB7-H3 antibody, or antigen -binding portion thereof comprises a heavy chain CDR set corresponding to antibody huAbl3vl, and a light chain CDR set
• the anti-hB7-H3 antibody, or antigen- binding portion thereof comprises a heavy chain variable region corresponding to antibody huAbl3vl, and a light chain variable region corresponding to antibody huAbl3vl.
• the anti-hB7-H3 antibody, or antigen-binding portion thereof comprises a heavy chain CDR set corresponding to antibody huAb3v2.5, and a light chain CDR set
• the anti-hB7-H3 antibody, or antigen- binding portion thereof comprises a heavy chain variable region corresponding to antibody huAb3v2.5, and a light chain variable region corresponding to antibody huAb3v2.5.
• the antibody, or antigen binding portion thereof binds cynomolgus B7-
• the antibody, or antigen binding portion thereof has a dissociation constant (K D ) to hB7-H3 selected from the group consisting of: at most about 10 7 M; at most about 10 s M; at most about 10 9 M; at most about 10 10 M; at most about 10 11 M; at most about 10 12 M; and at most 10 13 M.
• K D dissociation constant
• the antibody, or antigen binding portion thereof comprises a heavy chain immunoglobulin constant domain of a human IgM constant domain, a human IgGl constant domain, a human IgG2 constant domain, a human IgG3 constant domain, a human IgG4 constant domain, a human IgA constant domain, or a human IgE constant domain.
• the antibody is an IgG having four polypeptide chains which are two heavy chains and two light chains.
• the antibody, or antigen-binding portion thereof comprises the heavy chain immunoglobulin constant region domain is a human IgGl constant domain.
• the human IgGl constant domain comprises an amino acid sequence of SEQ ID NO: 159 or SEQ ID NO: 160.
• the present invention provides an isolated antibody, or antigen binding portion thereof, that binds to human B7-H3 (hB7-H3), wherein the antibody, or antigen binding portion thereof, comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 168 and a light chain comprising the amino acid sequence of SEQ ID NO: 169.
• the present invention provides an isolated antibody, or antigen binding portion thereof, that binds to human B7-H3 (hB7-H3), wherein the antibody, or antigen binding portion thereof, comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 170 and a light chain comprising the amino acid sequence of SEQ ID NO: 171.
• the present invention provides an isolated antibody, or antigen binding portion thereof, that binds to human B7-H3 (hB7-H3), wherein the antibody, or antigen binding portion thereof, comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain comprising the amino acid sequence of SEQ ID NO: 173.
• the antibody, or antigen binding portion thereof further comprises a light chain immunoglobulin constant domain comprising a human Ig kappa constant domain or a human Ig lambda constant domain.
• the anti-hB7-H3 antibody, or antigen-binding portion thereof competes with the antibody, or antigen binding portion thereof, of any one of the anti-hB7-H3 antibodies, or antigen-binding portions thereof, disclosed herein.
• the present invention provides a pharmaceutical composition
• a pharmaceutical composition comprising the anti-hB7-H3 antibody, or antigen binding portion thereof, as disclosed herein, and a pharmaceutically acceptable carrier.
• the present invention provides an anti-hB7-H3 Antibody Drug Conjugate (ADC) comprising an anti-hB7-H3 antibody disclosed herein conjugated to a drug via a linker.
• the drug is an auristatin or a pyrrolobenzodiazepine (PBD).
• the drug is a Bcl-xL inhibitor.
• the present invention provides an anti-hB7-H3 antibody drug conjugate (ADC) comprising a drug linked to an anti-human B7-H3 (hB7-H3) antibody by way of a linker, wherein the drug is a Bcl-xL inhibitor according to structural formula (Ila), (lib), (lie), or (lid): r 1 is selected from
• R 12 -Z 2b -, R'- Z 2b -, #-N(R 4 )-R 13 -Z 2b -, or #-R'-Z 2b - substituents are attached to Ar 2 at any Ar 2 atom capable of being substituted;
• Z 1 is selected from N, CH, C-halo, C-CH 3 and C-CN;
• Z 2a and Z 2b are each , independently from one another, selected from a bond, NR 6 , CR 6a R 6b , O, S, S(O), S(0) 2 , -NR 6 C(0)-,- NR 6a C(0)NR
• R' is o orr , wherein #, where attached to R' , is attached to R' at any R' atom capable of being substituted;
• X' is selected at each occurrence from -N(R 10 )- , -N(R 10 )C(O)-, -N(R 10 )S(O) 2 -, -S(0) 2 N(R 10 )-, and -0-;
• n is selected from 0-3;
• R 10 is independently selected at each occurrence from hydrogen, lower alkyl, heterocycle, aminoalkyl, G-alkyl, and -(CH 2 ) 2 -0-(CH 2 ) 2 -0-(CH 2 ) 2 -NH 2 ;
• G at each occurrence is independently selected from a polyol, a polyethylene glycol with between 4 and 30 repeating units, a salt and a moiety that is charged at physiological pH;
• SP is independently selected at each occurrence from oxygen, -S(0) 2 N(H)
• the antibody comprises a heavy chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 147 and a light chain variable domain comprising the amino acid sequence set forth in SEQ ID NO: 144; binds to B7- H3 (SEQ ID NO: 149) with a dissociation constant (K d ) of about 1 x 10 6 M or less, as determined by surface plasmon resonance; and/or inhibits tumor growth in an in vivo human small-cell lung carcinoma (SCLC) xenograft assay with a tumor growth inhibition % (TGI ) of at least about 50% relative to a human IgG antibody which is not specific for B7-H3, wherein the human IgG antibody is administered in the SCLC xenograft assay at the same dose and frequency as the anti-hB7-H3 antibody.
• SCLC small-cell lung carcinoma
• the ADC is a compound according to structural formula (I): wherein D is the Bcl-xL inhibitor drug of formula (Ila), (lib), (lie) or (lid); L is the linker; Ab is the anti-hB7-H3 antibody; LK represents a covalent linkage linking the linker (L) to the anti-hB7- H3 antibody (Ab); and m is an integer ranging from 1 to 20.
• G at each occurrence is a salt or a moiety that is charged at physiological pH.
• G at each occurrence is a salt of a carboxylate, a sulfonate, a
• G at each occurrence is a moiety that is charged at physiological pH selected from the group consisting of carboxylate, a sulfonate, a phosphonate, and an amine.
• G at each occurrence is a moiety containing a polyethylene glycol with between 4 and 30 repeating units, or a polyol.
• the polyol is a sugar.
• the ADC is of the formula (Ila) or formula (lid), and R' includes at least one substitutable nitrogen suitable for attachment to a linker.
• G is selected at each occurrence from:
• M is hydrogen or a positively charged counterion.
• Ar 1 is selected from and is optionally substituted with one or more substituents independently selected from halo, cyano, methyl, and halomethyl.
• Ar 1 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
• Ar is , optionally substituted with one or more substituents.
• Ar 2 is substituted with one or more solubilizing groups.
• each solubilizing group is, independently of the others, selected from a moiety containing a polyol, a polyethylene glycol with between 4 and 30 repeating units, a salt, or a moiety that is charged at physiological pH.
• Ar 2 is substituted with one or more solubilizing groups.
• each solubilizing group is, independently of the others, selected from a moiety containing a polyol, a polyethylene glycol with between 4 and 30 repeating units, a salt, or a moiety that is charged at physiological pH.
• Z 1 is N.
• Z 2 is O.
• R 1 is methyl or chloro.
• R 2 is hydrogen or methyl. In one embodiment, R 2 is hydrogen.
• Z 2b is O.
• Z 2b is NH or CH 2 .
• the ADC is a compound according to structural formula (Ila). In one embodiment, the ADC is a compound according to structural formula (Ila) which includes a core selected from structures (C.1)-(C.21):
• Y is optionally substituted Q-Cg alkylene; r is 0 or 1; and s is 1, 2 or 3.
• U is selected from N, O and CH, with the proviso that when U is O, then V and R are absent;
• R 20 is selected from H and Q-C4 alkyl;
• R 21 and R 21b are each, independently from one another, absent or selected from H, Q-C4 alkyl and G, where G is selected from a polyol, PEG4-30, a salt and a moiety that is charged at physiological pH;
• V and V b are each, independently from one another, absent or selected from a bond, and an optionally substituted alkylene;
• R 20 is selected from H and C 1 -C4 alkyl; and s is 1, 2 or 3.
• R b is selected from H, Q-C4 alkyl and J b -G or is optionally taken together with an atom of T to form a ring having between 3 and 7 atoms; J and J b are each, independently from one another, selected from optionally substituted Ci-C 8 alkylene and optionally substituted phenylene; T is selected from optionally substituted Ci-C 8 alkylene, CH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 ,
• G is selected from a polyol, PEG4-30, a salt and a moiety that is charged at physiological pH; and s is 1, 2 or 3.
• the ADC is a compound according to structural formula (lib).
• Y is optionally substituted Q-C 8 alkylene
• G is selected from a polyol, PEG4-30, and a moiety that is charged at physiological pH; r is 0 or 1; and s is 1, 2 or 3.
• the ADC is a compound according to structural formula (lie). In one embo ):
• Y is optionally substituted Q-Cg alkylene
• Y b is optionally substituted Q-Cg alkylene
• R 23 is selected from H and C -C 4 alkyl
• G is selected from a polyol, PEG4-30, a salt and a moiety that is charged at physiological pH.
• Y is optionally substituted Q-Cg alkylene
• Y b is optionally substituted Ci-C 8 alkylene
• Y c is optionally substituted Q-C 8 alkylene
• R 23 is selected from H and Q-C4 alkyl
• R 25 is Y b -G or is taken together with an atom of Y c to form a ring having 4-6 ring atoms
• G is selected from a polyol, PEG4-30, a salt and a moiety that is charged at physiological pH.
• the Bcl-xL inhibitor is selected from the group consisting of the following compounds modified in that the hydrogen corresponding to the # position of structural formula (Ila), (lib), (lie), or (lid) is not present forming a monoradical:
• the linker is cleavable by a lysosomal enzyme.
• the lysosomal enzyme is Cathepsin B.
• the linker comprises a segment according to structural formula (IV a), (IVb), (IVc), or (IVd):
• peptide represents a peptide (illustrated N ⁇ C, wherein peptide includes the amino and carboxy "termini”) a cleavable by a lysosomal enzyme;
• T represents a polymer comprising one or more ethylene glycol units or an alkylene chain, or combinations thereof;
• R is selected from hydrogen, C 1 6 alkyl, S0 3 H and CH 2 S0 3 H;
• R y is hydrogen or C 1 4 alkyl- (0) r -(Ci_4 alkylene -G 1 or C 1 4 alkyl-(N)-[(C 1 4 alkylene) ⁇ 1 ] 2 ;
• R z is C 1 4 alkyl-(0) r -(C 1 4 alkylene) s -G 2 ;
• G 1 is S0 3 H, C0 2 H, PEG 4-32, or sugar moiety;
• G 2 is S0 3 H, C0 2 H, or PEG 4-32 moiety;
• r is 0 or 1 ;
• s is 0 or 1 ;
• p is an integer ranging from 0 to 5 ;
• q is 0 or 1 ;
• x is 0 or 1 ;
• y is 0 or 1 ;
• / ⁇ represents the point of attachment of the linker
• the peptide is selected from the group consisting of Val-Cit; Cit-Val; Ala-Ala; Ala-Cit; Cit-Ala; Asn-Cit; Cit-Asn; Cit-Cit; Val-Glu; Glu-Val; Ser-Cit; Cit-Ser; Lys-Cit; Cit-Lys; Asp-Cit; Cit-Asp; Ala-Val; Val-Ala; Phe-Lys; Lys-Phe; Val-Lys; Lys-Val; Ala-Lys; Lys- Ala; Phe-Cit; Cit-Phe; Leu-Cit; Cit-Leu; Ile-Cit; Cit-Ile; Phe-Arg; Arg-Phe; Cit-Trp; and Trp-Cit.
• the lysosomal enzyme is ⁇ -glucuronidase or ⁇ -galactosidase.
• the linker comprises a segment according to structural formula (Va), (Vb), (Vc), (Vd), or (Ve):
• the linker comprises a segment according to structural formula (Villa), (Vlllb), or (VIII
• the linker comprises a polyethylene glycol segment having from 1 to 6 ethylene glycol units.
• m is 2, 3 or 4.
• linker L is selected from IVa or IVb.
• linker L is selected from the group consisting of IVa.1 -IVa.8, IVb. l-
• the linker L is selected from the group consisting of IVb.2, IVc.5, IVc.6, IVc.7, IVd.4, Vb.9, Vila.1 , VIIa.3, VIIc.1 , VIIc.4, and VIIc.5, wherein the maleimide of each linker has reacted with the antibody Ab, forming a covalent attachment as either a succinimide (closed form) or succinamide (open form).
• the linker L is selected from the group consisting of IVb.2, IVc.5, IVc.6, IVd.4, Vlla.l, VIIa.3, VIIc. l, VIIc.4, VIIc.5, wherein the maleimide of each linker has reacted with the antibody Ab, forming a covalent attachment as either a succinimide (closed form) or succinamide (open form).
• the linker L is selected from the group consisting of IVb.2, VIIa.3, IVc.6, and VIIc.l, wherein ⁇ is the attachment point to drug D and @ is the attachment point to the LK, wherein when the linker is in the open form as shown below, @ can be either at the a-position or ⁇ - position
• LK is a linkage formed with an amino group on the anti-hB7H3 antibody
• LK is an amide or a thiourea.
• LK is a linkage formed with a sulfhydryl group on the anti-hB7-H3 antibody Ab.
• LK is a thioether
• LK is selected from the group consisting of amide, thiourea and thioether; and m is an integer ranging from 1 to 8.
• D is a Bcl-xL inhibitor as described herein;
• L is selected from the group consisting of linkers IVa. l-IVa.8, IVb.l-IVb.19, IVc. l-IVc.7, IVd. l-IVd.4, Va. l-Va.12, Vb.l-Vb. lO, Vc. l-Vc.l l, Vd.l-Vd.6, Ve.l-Ve.2, Vla.l, VIc.l-Vlc.2, VId. l-VId.4, VIIa. l-VIIa.4, VIIb. l-VIIb.8, and VIIc.l-VIIc.6, wherein each linker has reacted with the antibody, Ab, forming a covalent attachment;
• LK is thioether; and
• m is an integer ranging from 1 to 8.
• D is the Bcl-xL inhibitor selected from the group consisting of the following compounds modified in that the hydrogen corresponding to the # position of structural formula (Ila), (lib), (lie), or (lid) is not present, forming a monoradical:
• L is selected from the group consisting of linkers IVb.2, IVc.5, IVc.6, IVc.7, IVd.4, Vb.9, Ve i l , Vlla. l , VIIa.3, VIIc. l , VIIc.4, and VIIc.5 in either closed or open forms;
• LK is thioether
• n is an integer ranging from 2 to 4.
• the ADC is selected from the group consisting of formulae i-vi:
• Ab is an anti-hB7-H3 antibody, wherein the anti-hB7-H3 antibody comprises a heavy chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 35, a heavy chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 34, and a heavy chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 33; and a light chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 39, a light chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 38, and a light chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 37.
• the Ab is an anti-hB7-H3 antibody, wherein the anti-hB7H3 antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 147, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 144.
• Ab is an anti-hB7-H3 antibody, wherein the anti-hB7-H3 antibody comprises a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 160 and/or a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 161.
• Ab is an anti-hB7-H3 antibody, wherein the anti-hB7-H3 antibody comprises a heavy chain comprising the amino acid sequence set forth in
• Ab is an anti-hB7-H3 antibody, wherein the anti-hB7-H3 antibody comprises a heavy chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 12, a heavy chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 140, and a heavy chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 10; and a light chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 15, a light chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 7, and a light chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 136.
• the anti-hB7-H3 antibody comprises a heavy chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 12, a heavy chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 140, and a heavy chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
• the Ab is an anti-hB7-H3 antibody, wherein the anti-hB7H3 antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 139, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 135.
• Ab is an anti-hB7-H3 antibody, wherein the anti-hB7-H3 antibody comprises a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 160 and/or a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO: 161.
• Ab is an anti-hB7-H3 antibody, wherein the anti-hB7-H3 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 170, and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 171.
• n is an integer from 2 to 6. In one embodiment, m is 2.
• the ADC comprises an anti-hB7-H3 antibody comprising a heavy chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 12, a heavy chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 140, and a heavy chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 10; a light chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 15, a light chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 7, and a light chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 136 or 138.
• the ADC comprises an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 139, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 135.
• the ADC comprises an the antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 139, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 137.
• the ADC comprises an antibody comprising a light chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 39, a light chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 38, and a light chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 37; and a heavy chain CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO: 35, a heavy chain CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO: 34, and a heavy chain CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO: 33.
• the ADC comprises an antibody comprising a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 147, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 144.
• the ADC is selected from the group consisting of huAb3v2.5-CZ, huAb3v2.5-TX, huAb3v2.5-TV, huAb3v2.5-YY, huAb3v2.5-AAA, huAb3v2.5-AAD, huAb3v2.6- CZ, huAb3v2.6-TX, huAb3v2.6-TV, huAb3v2.6-YY, huAb3v2.6-AAD, huAbl3vl-CZ, huAbl3vl- TX, huAbl3vl-TV, huAbl3vl-YY, huAbl3vl-AAA, huAbl3vl-AAD, wherein CZ, TX, TV, YY, AAA, and AAD are synthons disclosed in Table B, and wherein the conjugated synthons are either in open or closed form.
• the present invention provides a pharmaceutical composition comprising an effective amount of an ADC described herein, and a pharmaceutically acceptable carrier.
• the present invention provides a pharmaceutical composition
• a pharmaceutical composition comprising an ADC mixture comprising a plurality of ADCs described herein, and a pharmaceutically acceptable carrier.
• the ADC mixture has an average drug to antibody ratio (DAR) of 1.5 to
• the ADC mixture comprises ADCs each having a DAR of 1.5 to 8.
• the present invention provides a method for treating cancer, comprising administering a therapeutically effective amount of an ADC described herein to a subject in need thereof.
• the cancer is selected from the group consisting of small cell lung cancer, non small cell lung cancer, breast cancer, ovarian cancer, a glioblastoma, prostate cancer, pancreatic cancer, colon cancer, gastric cancer, melanoma, hepatocellular carcinoma, head and neck cancer, kidney cancer, leukemia, e.g., acute myeloid leukemia (AML), and lymphoma, e.g., non- Hodgkin's lymphoma (NHL).
• AML acute myeloid leukemia
• NHL non- Hodgkin's lymphoma
• the cancer is a squamous cell carcinoma.
• the squamous cell carcinoma is squamous lung cancer or squamous head and neck cancer.
• the cancer is triple negative breast cancer.
• the cancer is non-small cell lung cancer.
• the cancer is characterized as having an activating EGFR mutation.
• the activating EGFR mutation is selected from the group consisting of an exon 19 deletion mutation, a single-point substitution mutation L858R in exon 21, a T790M point mutation, and combinations thereof.
• the present invention provides a method for inhibiting or decreasing solid tumor growth in a subject having a solid tumor, said method comprising administering an effective amount of an ADC described herein to the subject having the solid tumor, such that the solid tumor growth is inhibited or decreased.
• the solid tumor is a non-small cell lung carcinoma.
• the ADC is administered in combination with an additional agent or an additional therapy.
• the additional agent is selected from the group consisting of an anti-PDl antibody (e.g. pembrolizumab), an anti-PD-Ll antibody (e.g., atezolizumab), an anti-CTLA-4 antibody (e.g. ipilimumab), a MEK inhibitor (e.g. trametinib), an ERK inhibitor, a BRAF inhibitor (e.g. dabrafenib), osimertinib, erlotinib, gefitinib, sorafenib, a CDK9 inhibitor (e.g. dinaciclib), a MCL-1 inhibitor, temozolomide, a Bcl-2 inhibitor (e.g.
• an anti-PDl antibody e.g. pembrolizumab
• an anti-PD-Ll antibody e.g., atezolizumab
• an anti-CTLA-4 antibody e.g. ipilimumab
• MEK inhibitor e.
• a Bcl-xL inhibitor ibrutinib, a mTOR inhibitor (e.g. everolimus), a PI3K inhibitor (e.g. buparlisib), duvelisib, idelalisib, an AKT inhibitor, a HER2 inhibitor (e.g. lapatinib), a taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel), an ADC comprising an auristatin, an ADC comprising a PBD (e.g. rovalpituzumab tesirine), an ADC comprising a maytansinoid (e.g. TDMl), a TRAIL agonist, a proteasome inhibitor (e.g. bortezomib), and a nicotinamide phosphoribosyltransferase (NAMPT) inhibitor.
• a mTOR inhibitor e.g. everolimus
• the anti-B7-H3 ADCs of the invention are administered in combination with venetoclax to a human subject for the treatment of small cell lung cancer (SCLC).
• SCLC small cell lung cancer
• the additional therapy is radiation.
• the additional agent is a chemotherapeutic agent.
• the present invention provides a process for the preparation of an ADC according to structural formula (I):
• D is the Bcl-xL inhibitor drug of formula (Ila), (lib), (lie), or (lid) as disclosed herein;
• L is the linker as disclosed herein;
• Ab is an hB7-H3 antibody, wherein the hB7-H3 antibody comprises the heavy and light chain CDRs of huAb3v2.5, huAb3v2.6, or huAbl3vl ;
• LK represents a covalent linkage linking linker L to antibody Ab
• n is an integer ranging from 1 to 20;
• ADC is optionally purified by hydrophobic interaction chromatography.
• n is 2.
• the present invention provides an ADC prepared by the process as described above.
• Figure 1 is a graphical representation of the epitope grouping of murine anti-B7-H3 hybridoma antibodies as determined by pair-wise binding assays.
• Figure 2 depicts an antibody reduction, modification with a maleimide derivative to give a thiosuccinimide intermediate, and subsequent hydrolysis of thiosuccinimide moiety
• FIG. 3 depicts the structure of an antibody-maleimidocaproyl-vc-PABA-MMAE ADC.
• Figure 4 depicts the structure of a PBD dimer (SGD-1882) conjugated to an antibody (Ab) via a maleimidocaproyl-valine-alanine linker (collectively referred to as SGD-1910).
• Figure 5 depicts the MS characterization of light chain and heavy chain of huAbl3vl 1) prior to conjugation, 2) after conjugation to a maleimide derivative to give a thiosuccinimide intermediate and 3) post pH 8-mediated hydrolysis of the thiosuccinimide ring.
• Various aspects of the invention relate to anti-B7-H3 antibodies and antibody fragments, anti- B7-H3 ADCs, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such antibodies and fragments.
• Methods of using the antibodies, fragments, and ADCs described herein to detect human B7-H3, to inhibit human B7-H3 activity (in vitro or in vivo), and to treat cancers are also encompassed by the invention.
• the invention provides anti-B7-H3 ADCs, including ADCs comprising Bcl-xL inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the ADCs, methods of making the ADCs, and various methods of using the ADCs.
• the ADCs disclosed herein are "modular” in nature.
• various specific embodiments of the various “modules” comprising the ADCs, as well as the synthons useful for synthesizing the ADCs are described.
• specific embodiments of antibodies, linkers, and Bcl-xL inhibitors that may comprise the ADCs and synthons are described. It is intended that all of the specific embodiments described may be combined with each other as though each specific combination were explicitly described individually.
• ADCs and/or ADC synthons described herein may be in the form of salts, and in certain embodiments, particularly
• the compounds of the present disclosure that possess a sufficiently acidic, a sufficiently basic, or both functional groups can react with any of a number of inorganic bases, and inorganic and organic acids, to form a salt.
• compounds that are inherently charged, such as those with a quaternary nitrogen can form a salt with an appropriate counterion, e.g., a halide such as a bromide, chloride, or fluoride.
• Acids commonly employed to form acid addition salts are inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenyl- sulfonic acid, carbonic acid, succinic acid, citric acid, etc.
• Base addition salts include those derived from inorganic bases, such as ammonium and alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like.
• anti-B7-H3 antibody refers to an antibody that specifically binds to B7-H3.
• An antibody "which binds" an antigen of interest, i.e., B7-H3, is one capable of binding that antigen with sufficient affinity such that the antibody is useful in targeting a cell expressing the antigen.
• the antibody specifically binds to human B7-H3 (hB7-H3). Examples of anti- B7-H3 antibodies are disclosed in the examples below.
• anti- B7-H3 antibody refers to an antibody which binds to wild type B7-H3 (e.g., a 4IgB7-H3 isoform of B7-H3) or any variant of B7-H3.
• wild type B7-H3 e.g., a 4IgB7-H3 isoform of B7-H3
• the amino acid sequence of wild type human B7-H3 is provided below as SEQ ID NO: 149, where the signal peptide (amino acid residues 1-28) is underlined.
• the antibody or ADC binds human B7-H3 as defined in SEQ ID NO: 149.
• the extracellular domain (ECD) of human B7-H3 is provided in SEQ ID NO: 152 (inclusive of a His tag).
• the antibody of ADC binds the ECD of human B7-H3 as described in the ECD of SEQ ID NO: 152.
• telomere binding in reference to the interaction of an antibody or an ADC with a second chemical species, mean that the interaction is dependent upon the presence of a particular structure (e.g., an antigenic determinant or epitope) on the chemical species; for example, an antibody recognizes and binds to a specific protein structure rather than to proteins generally. If an antibody or ADC is specific for epitope "A”, the presence of a molecule containing epitope A (or free, unlabeled A), in a reaction containing labeled "A” and the antibody, will reduce the amount of labeled A bound to the antibody or ADC.
• a particular structure e.g., an antigenic determinant or epitope
• an antibody "binds specifically" to a target if the antibody, when labeled, can be competed away from its target by the corresponding non-labeled antibody.
• an antibody specifically binds to a target, e.g., B7-H3, if the antibody has a K D for the target of at least about 10 4 M, 10 s M, 10 6 M, 10-7 M, 10 s M, 10 9 M, 10 10 M, 10 11 M, 10 12 M, or less (less meaning a number that is less than 10 u , e.g. 10 13 ).
• the term "specific binding to B7-H3" or “specifically binds to B7- H3,” as used herein, refers to an antibody or an ADC that binds to B7-H3 and has a dissociation constant (K D ) of 1.0 x 10 7 M or less, as determined by surface plasmon resonance. It shall be understood, however, that the antibody or ADC may be capable of specifically binding to two or more antigens which are related in sequence. For example, in one embodiment, an antibody can specifically bind to both human and a non-human (e.g., mouse or non-human primate) orthologs of B7-H3.
• K D dissociation constant
• antibody refers to an immunoglobulin molecule that specifically binds to an antigen and comprises a heavy (H) chain(s) and a light (L chain(s).
• Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as HCVR or VH) and a heavy chain constant region.
• the heavy chain constant region is comprised of three domains, CHI, CH2 and CH3.
• Each light chain is comprised of a light chain variable region (abbreviated herein as LCVR or VL) and a light chain constant region.
• the light chain constant region is comprised of one domain, CL.
• VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR).
• CDR complementarity determining regions
• FR framework regions
• Each VH and VL is composed of three CDRs and four FRs, arranged from amino- terminus to carboxy-terminus in the following order: FRl, CDRl, FR2, CDR2, FR3, CDR3, FR4.
• An antibody can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY) and class (e.g., IgGl, IgG2, IgG 3, IgG4, IgAl and IgA2) or subclass.
• an antibody is not intended to include antigen binding portions of an antibody (defined below), it is intended, in certain embodiments, to include a small number of amino acid deletions from the carboxy end of the heavy chain(s).
• an antibody comprises a heavy chain having 1 -5 amino acid deletions the carboxy end of the heavy chain.
• an antibody is a monoclonal antibody which is an IgG, having four polypeptide chains, two heavy (H) chains, and two light (L chains) that can bind to hB7-H3.
• an antibody is a monoclonal IgG antibody comprising a lambda or a kappa light chain.
• antigen binding portion or “antigen binding fragment” of an antibody (or simply “antibody portion” or “antibody fragment”), as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g. , hB7-H3). It has been shown that the antigen binding function of an antibody can be performed by fragments of a full-length antibody. Such antibody embodiments may also be bispecific, dual specific, or multi-specific formats; specifically binding to two or more different antigens.
• binding fragments encompassed within the term "antigen binding portion" of an antibody include (i) a Fab fragment, a monovalent fragment consisting of the VL, VH, CL and CHI domains; (ii) a F(ab')2 fragment, a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a Fd fragment consisting of the VH and CHI domains; (iv) a Fv fragment consisting of the VL and
• VH domains of a single arm of an antibody (v) a dAb fragment (Ward et al., (1989) Nature 341 :544- 546, Winter et al., PCT publication WO 90/05144 Al herein incorporated by reference), which comprises a single variable domain; and (vi) an isolated complementarity determining region (CDR).
• a dAb fragment (Ward et al., (1989) Nature 341 :544- 546, Winter et al., PCT publication WO 90/05144 Al herein incorporated by reference), which comprises a single variable domain; and (vi) an isolated complementarity determining region (CDR).
• the two domains of the Fv fragment, VL and VH are coded for by separate genes, they can be joined, using recombinant methods, by a synthetic linker that enables them to be made as a single protein chain in which the VL and VH regions pair to form monovalent molecules (known as single chain Fv (scF
• single chain antibodies are also intended to be encompassed within the term "antigen binding portion" of an antibody.
• scFv molecules may be incorporated into a fusion protein.
• Other forms of single chain antibodies, such as diabodies are also encompassed.
• Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites (see e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R.J., et al. (1994) Structure 2: 1121-1123).
• Such antibody binding portions are known in the art (Kontermann and Dubel eds., Antibody Engineering (2001) Springer-Verlag. New York. 790 pp. (ISBN 3-540-41354-5).
• An IgG is a class of antibody comprising two heavy chains and two light chains arranged in a Y-shape.
• An IgG constant domain refers to a heavy or light chain constant domain.
• Exemplary human IgG heavy chain and light chain constant domain amino acid sequences are known in the art and represented below in Table A.
• an “isolated antibody”, as used herein, is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds B7-H3 is substantially free of antibodies that specifically bind antigens other than B7-H3).
• An isolated antibody that specifically binds B7-H3 may, however, have cross-reactivity to other antigens, such as B7-H3 molecules from other species.
• an isolated antibody may be substantially free of other cellular material and/or chemicals.
• the term “humanized antibody” refers to antibodies which comprise heavy and light chain variable region sequences from a nonhuman species (e.g.
• humanized antibody is an antibody or a variant, derivative, analog or fragment thereof which immunospecifically binds to an antigen of interest and which comprises a framework (FR) region having substantially the amino acid sequence of a human antibody and a complementary determining region (CDR) having substantially the amino acid sequence of a non-human antibody.
• FR framework
• CDR complementary determining region
• the term "substantially" in the context of a CDR refers to a CDR having an amino acid sequence at least 80%, preferably at least 85%, at least 90%, at least 95%, at least 98% or at least 99% identical to the amino acid sequence of a non-human antibody CDR.
• a humanized antibody comprises substantially all of at least one, and typically two, variable domains (Fab, Fab', F(ab') 2 , FabC, Fv) in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin (i.e., donor antibody) and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence.
• a humanized antibody also comprises at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
• a humanized antibody contains both the light chain as well as at least the variable domain of a heavy chain.
• the antibody also may include the CHI, hinge, CH2, CH3, and CH4 regions of the heavy chain.
• a humanized antibody only contains a humanized light chain.
• a humanized antibody only contains a humanized heavy chain.
• a humanized antibody only contains a humanized variable domain of a light chain and/or humanized heavy chain.
• the humanized antibody can be selected from any class of immunoglobulins, including IgM, IgG, IgD, IgA and IgE, and any isotype, including without limitation IgGl, IgG2, IgG3 and IgG4.
• the humanized antibody may comprise sequences from more than one class or isotype, and particular constant domains may be selected to optimize desired effector functions using techniques well-known in the art.
• Kabat numbering “Kabat definitions,” and “Kabat labeling” are used interchangeably herein. These terms, which are recognized in the art, refer to a system of numbering amino acid residues which are more variable (i.e., hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding portion thereof (Kabat et al. (1971) Ann. NY Acad, Sci. 190:382-391 and, Kabat, E.A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH
• the hypervariable region ranges from amino acid positions 31 to 35 for CDR1, amino acid positions 50 to 65 for CDR2, and amino acid positions 95 to 102 for CDR3.
• the hypervariable region ranges from amino acid positions 24 to 34 for CDR1, amino acid positions 50 to 56 for CDR2, and amino acid positions 89 to 97 for CDR3.
• CDR refers to the complementarity determining region within antibody variable sequences.
• CDR1 CDR1
• CDR2 CDR2
• CDR3 CDR3
• HC CDR1 HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3
• CDR set refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs have been defined differently according to different systems. The system described by Kabat (Kabat et al., Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md.
• CDR boundary definitions may not strictly follow one of the above systems, but will nonetheless overlap with the Kabat CDRs, although they may be shortened or lengthened in light of prediction or experimental findings that particular residues or groups of residues or even entire CDRs do not significantly impact antigen binding.
• the methods used herein may utilize CDRs defined according to any of these systems, although preferred embodiments use Kabat or Chothia defined CDRs.
• framework or “framework sequence” refers to the remaining sequences of a variable region minus the CDRs. Because the exact definition of a CDR sequence can be determined by different systems, the meaning of a framework sequence is subject to
• the six CDRs (CDR-L1, CDR-L2, and CDR-L3 of light chain and CDR-Hl, CDR-H2, and CDR-H3 of heavy chain) also divide the framework regions on the light chain and the heavy chain into four sub-regions (FR1, FR2, FR3 and FR4) on each chain, in which CDR1 is positioned between FR1 and FR2, CDR2 between FR2 and FR3, and CDR3 between FR3 and FR4.
• a framework region represents the combined FR's within the variable region of a single, naturally occurring immunoglobulin chain.
• a FR represents one of the four sub- regions
• FRs represents two or more of the four sub- regions constituting a framework region.
• the framework and CDR regions of a humanized antibody need not correspond precisely to the parental sequences, e.g., the donor antibody CDR or the consensus framework may be mutagenized by substitution, insertion and/or deletion of at least one amino acid residue so that the CDR or framework residue at that site does not correspond to either the donor antibody or the consensus framework. In a preferred embodiment, such mutations, however, will not be extensive. Usually, at least 80%, preferably at least 85%, more preferably at least 90%, and most preferably at least 95% of the humanized antibody residues will correspond to those of the parental FR and CDR sequences.
• the term "consensus framework" refers to the framework region in the consensus immunoglobulin sequence.
• the term "consensus immunoglobulin sequence” refers to the sequence formed from the most frequently occurring amino acids (or nucleotides) in a family of related immunoglobulin sequences (See e.g., Winnaker, From Genes to Clones (Verlagsgesellschaft, Weinheim, Germany 1987). In a family of immunoglobulins, each position in the consensus sequence is occupied by the amino acid occurring most frequently at that position in the family. If two amino acids occur equally frequently, either can be included in the consensus sequence.
• human acceptor framework is meant to refer to a framework of an antibody or antibody fragment thereof comprising the amino acid sequence of a VH or VL framework derived from a human antibody or antibody fragment thereof or a human consensus sequence framework into which CDR's from a non-human species may be incorporated.
• Percent (%) amino acid sequence identity with respect to a peptide or polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific peptide or polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for measuring alignment, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
• the invention includes an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to an amino acid sequence set forth in any one of SEQ ID NOs: 1 to 148.
• multivalent antibody is used herein to denote an antibody comprising two or more antigen binding sites.
• the multivalent antibody may be engineered to have the three or more antigen binding sites, and is generally not a naturally occurring antibody.
• multispecific antibody refers to an antibody capable of binding two or more unrelated antigens.
• the multispecific antibody is a bispecific antibody that is capable of binding to two unrelated antigens, e.g., a bispecific antibody, or antigen-binding portion thereof, that binds B7-H3 and CD3.
• the term "dual variable domain" or “DVD,” as used interchangeably herein, are antigen binding proteins that comprise two or more antigen binding sites and are tetravalent or multivalent binding proteins. Such DVDs may be monospecific, i.e. , capable of binding one antigen or multispecific, i.e. capable of binding two or more antigens.
• DVD binding proteins comprising two heavy chain DVD polypeptides and two light chain DVD polypeptides are referred to a DVD Ig. Each half of a DVD Ig comprises a heavy chain DVD polypeptide, and a light chain DVD
• Each binding site comprises a heavy chain variable domain and a light chain variable domain with a total of 6 CDRs involved in antigen binding per antigen binding site.
• the CDRs described herein are used in an anti-B7-H3 DVD.
• chimeric antigen receptor refers to a recombinant protein comprising at least (1) an antigen-binding region, e.g., a variable heavy or light chain of an antibody, (2) a transmembrane domain to anchor the CAR into a T cell, and (3) one or more intracellular signaling domains.
• activity includes activities such as the binding specificity/affinity of an antibody or ADC for an antigen, for example, an anti-hB7-H3 antibody that binds to an hB7-H3 antigen and/or the neutralizing potency of an antibody, for example, an anti-hB7-H3 antibody whose binding to hB7- H3 inhibits the biological activity of hB7-H3, e.g., inhibition of proliferation of B7-H3 expressing cell lines, e.g., human H146 lung carcinoma cells, human H1650 lung carcinoma cells, or human EBC1 lung carcinoma cells.
• non small-cell lung carcinoma (NSCLC) xenograft assay refers to an in vivo assay used to determine whether an anti-B7-H3 antibody or ADC, can inhibit tumor growth (e.g., further growth) and/or decrease tumor growth resulting from the transplantation of NSCLC cells into an immunodeficient mouse.
• An NSCLC xenograft assay includes transplantation of NSCLC cells into an immunodeficient mouse such that a tumor grows to a desired size, e.g., 200-250 mm 3 , whereupon the antibody or ADC is administered to the mouse to determine whether the antibody or ADC can inhibit and/or decrease tumor growth.
• the activity of the antibody or ADC is determined according to the percent tumor growth inhibition ( TGI) relative to a control antibody, e.g., a human IgG antibody (or collection thereof) which does not specifically bind tumor cells, e.g., is directed to an antigen not associated with cancer or is obtained from a source which is noncancerous (e.g., normal human serum).
• TGI percent tumor growth inhibition
• the antibody (or ADC) and the control antibody are administered to the mouse at the same dose, with the same frequency, and via the same route.
• the mouse used in the NSCLC xenograft assay is a severe combined immunodeficiency (SCID) mouse and/or an athymic CD-I nude mouse.
• SCID severe combined immunodeficiency
• SCLC small-cell lung carcinoma
• xenograft assay refers to an in vivo assay used to determine whether an anti-B7-H3 antibody or ADC, can inhibit tumor growth (e.g., further growth) and/or decrease tumor growth resulting from the transplantation of SCLC cells into an immunodeficient mouse.
• An SCLC xenograft assay includes transplantation of SCLC cells into an immunodeficient mouse such that a tumor grows to a desired size, e.g., 200-250 mm 3 , whereupon the antibody or ADC is administered to the mouse to determine whether the antibody or ADC can inhibit and/or decrease tumor growth.
• the activity of the antibody or ADC is determined according to the percent tumor growth inhibition ( TGI) relative to a control antibody, e.g., a human IgG antibody (or collection thereof) which does not specifically bind tumor cells, e.g., is directed to an antigen not associated with cancer or is obtained from a source which is noncancerous (e.g., normal human serum).
• TGI percent tumor growth inhibition
• the antibody (or ADC) and the control antibody are administered to the mouse at the same dose, with the same frequency, and via the same route.
• the mouse used in the NSCLC xenograft assay is a severe combined
• SCLC cells immunodeficiency mice and/or an athymic CD-I nude mouse.
• SCLC cells that may be used in the SCLC xenograft assay include, but are not limited to, H146 cells (NCI-H146 cells [H146] (ATCC ® HTB-173TM)), and H847 cells (NCI-H847 [H847] (ATCC ® CRL-5846TM)).
• epipe refers to a region of an antigen that is bound by an antibody or ADC.
• epitope determinants include chemically active surface groupings of molecules such as amino acids, sugar side chains, phosphoryl, or sulfonyl, and, in certain embodiments, may have specific three dimensional structural characteristics, and/or specific charge characteristics.
• an antibody is said to specifically bind an antigen when it preferentially recognizes its target antigen in a complex mixture of proteins and/or macromolecules.
• surface plasmon resonance refers to an optical phenomenon that allows for the analysis of real-time biospecific interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIAcore system (Pharmacia
• k on or " k a ", as used herein, is intended to refer to the on rate constant for association of an antibody to the antigen to form the antibody/antigen complex.
• k d is intended to refer to the off rate constant for dissociation of an antibody from the antibody/antigen complex.
• K D is intended to refer to the equilibrium dissociation constant of a particular antibody-antigen interaction (e.g., huAbl3 antibody and B7-H3). K D is calculated by k a / k d .
• competitive binding refers to a situation in which a first antibody competes with a second antibody, for a binding site on a third molecule, e.g., an antigen. In one embodiment, competitive binding between two antibodies is determined using FACS analysis.
• competitive binding assay is an assay used to determine whether two or more antibodies bind to the same epitope.
• a competitive binding assay is a competition fluorescent activated cell sorting (FACS) assay which is used to determine whether two or more antibodies bind to the same epitope by determining whether the fluorescent signal of a labeled antibody is reduced due to the introduction of a non-labeled antibody, where competition for the same epitope will lower the level of fluorescence.
• FACS competition fluorescent activated cell sorting
• label refers to an antibody, or an antigen binding portion thereof, with a label incorporated that provides for the identification of the binding protein, e.g., an antibody.
• the label is a detectable marker, e.g. , incorporation of a radiolabeled amino acid or attachment to a polypeptide of biotinyl moieties that can be detected by marked avidin (e.g. , streptavidin containing a fluorescent marker or enzymatic activity that can be detected by optical or colorimetric methods).
• markers for polypeptides include, but are not limited to, the following: radioisotopes or radionuclides (e.g.
• fluorescent labels e.g. , FITC, rhodamine, lanthanide phosphors
• enzymatic labels e.g. , horseradish peroxidase, luciferase, alkaline phosphatase
• chemiluminescent markers e.g. , biotinyl groups
• predetermined polypeptide epitopes recognized by a secondary reporter e.g. , leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags
• magnetic agents such as gadolinium chelates.
• an ADC refers to a binding protein, such as an antibody or antigen binding fragment thereof, chemically linked to one or more chemical drug(s) (also referred to herein as agent(s), warhead(s), and payload(s)) that may optionally be therapeutic or cytotoxic agents.
• an ADC includes an antibody, a drug, (e.g. a cytotoxic drug), and a linker that enables attachment or conjugation of the drug to the antibody.
• An ADC typically has anywhere from 1 to 8 drugs conjugated to the antibody, including drug loaded species of 2, 4, 6, or 8.
• Non-limiting examples of drugs that may be included in the ADCs are mitotic inhibitors, antitumor antibiotics, immunomodulating agents, vectors for gene therapy, alkylating agents, antiangiogenic agents, antimetabolites, boron-containing agents, chemoprotective agents, hormones, antihormone agents, corticosteroids, photoactive therapeutic agents, oligonucleotides, radionuclide agents, topoisomerase inhibitors, kinase inhibitors (e.g., TEC-family kinase inhibitors and serine/threonine kinase inhibitors), and radiosensitizers.
• the drug is a Bcl-xL inhibitor.
• anti-B7-H3 antibody drug conjugate or "anti-B7-H3 ADC”, used
• the anti- B7-H3 ADC comprises antibody huAbl3vl, huAb3v2.5, or huAb3v2.6 conjugated to an auristatin, e.g., MMAE or MMAF.
• the anti-B7-H3 ADC comprises antibody huAbl3vl, huAb3v2.5, or huAb3v2.6 conjugated to a Bcl-xL inhibitor.
• the anti-B7- H3 ADC binds to human B7-H3 (hB7-H3).
• Bcl-xL inhibitor refers to a compound which antagonizes Bcl-xL activity in a cell.
• a Bcl-xL inhibitor promotes apoptosis of a cell by inhibiting Bcl-xL activity.
• auristatin refers to a family of antimitotic agents. Auristatin derivatives are also included within the definition of the term “auristatin”. Examples of auristatins include, but are not limited to, auristatin E (AE), monomethylauristatin E (MMAE),
• MMAF monomethylauristatin F
• an anti- B7-H3 antibody described herein is conjugated to an auristatin to form an anti-B7-H3 ADC.
• Ab-vcMMAE is used to refer to an ADC comprising an antibody conjugated to monomethylauristatin E (MMAE) via a maleimidocaproyl valine citrulline p- aminobenzyloxycarbamyl (PABA) linker.
• MMAE monomethylauristatin E
• PABA p- aminobenzyloxycarbamyl
• mcMMAF is used to refer to a linker/drug combination of maleimidocaproyl-monomethylauristatin F (MMAF).
• DAR drug-to-antibody ratio
• Bcl-xL inhibitor a drug that is attached to the antibody of the ADC.
• the DAR of an ADC can range from 1 to 8, although higher loads, e.g., 20, are also possible depending on the number of linkage site on an antibody.
• the term DAR may be used in reference to the number of drugs loaded onto an individual antibody, or, alternatively, may be used in reference to the average or mean DAR of a group of ADCs.
• undesired ADC species refers to any drug loaded species which is to be separated from an ADC species having a different drug load.
• the term undesired ADC species may refer to drug loaded species of 6 or more, i.e., ADCs with a DAR of 6 or more, including DAR6, DAR7, DAR8, and DAR greater than 8 (i.e., drug loaded species of 6, 7, 8, or greater than 8).
• the term undesired ADC species may refer to drug loaded species of 8 or more, i.e., ADCs with a DAR of 8 or more, including DAR8, and DAR greater than 8 (i.e., drug loaded species of 8, or greater than 8).
• ADC mixture refers to a composition containing a heterogeneous
• an ADC mixture contains ADCs having a distribution of DARs of 1 to 8, e.g., 1.5, 2, 4, 6, and 8 (i.e., drug loaded species of 2, 4, 6, and 8). Notably, degradation products may result such that DARs of 1, 3, 5, and 7 may also be included in the mixture. Further, ADCs within the mixture may also have DARs greater than 8.
• the ADC mixture results from interchain disulfide reduction followed by conjugation.
• the ADC mixture comprises both ADCs with a DAR of 4 or less (i.e., a drug loaded species of 4 or less) and ADCs with a DAR of 6 or more (i.e., a drug loaded species of 6 or more).
• a "xenograft assay” refers to a human tumor xenograft assay, wherein human tumor cells are transplanted, either under the skin or into the organ type in which the tumor originated, into immunocompromised mice that do not reject human cells.
• cancer is meant to refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
• examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies.
• cancers include glioblastoma, acute myeloid leukemia (AML), non- Hodgkin's lymphoma (NHL), non-small cell lung cancer, lung cancer, colon cancer, colorectal cancer, head and neck cancer, breast cancer (e.g., triple negative breast cancer), pancreatic cancer, squamous cell tumors, squamous cell carcinoma (e.g., squamous cell lung cancer or squamous cell head and neck cancer), anal cancer, skin cancer, and vulvar cancer.
• the antibodies or ADCs of the invention are administered to a patient having a tumor(s) that overexpresses B7-H3.
• the antibodies or ADCs of the invention are administered to a patient having a solid tumor which is likely to over-express B7-H3. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having squamous cell non-small cell lung cancer (NSCLC). In one embodiment, the antibodies or ADCs of the invention are administered to a patient having solid tumors, including advanced solid tumors. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having prostate cancer. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having non-small cell lung cancer. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having a glioblastoma.
• NSCLC squamous cell non-small cell lung cancer
• the antibodies or ADCs of the invention are administered to a patient having colon cancer. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having head and neck cancer. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having kidney cancer. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having clear cell renal cell carcinoma. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having glioma. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having melanoma. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having pancreatic cancer.
• the antibodies or ADCs of the invention are administered to a patient having gastric cancer. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having ovarian cancer. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having colorectal cancer. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having renal cancer. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having small cell lung cancer. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having hepatocellular carcinoma. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having hypopharyngeal squamous cell carcinoma.
• the antibodies or ADCs of the invention are administered to a patient having neuroblastoma. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having breast cancer. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having endometrial cancer. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having urothelial cell carcinoma. In one embodiment, the antibodies or ADCs of the invention are administered to a patient having acute myeloid leukemia (AML). In one embodiment, the antibodies or ADCs of the invention are administered to a patient having non-Hodgkin's lymphoma (NHL).
• AML acute myeloid leukemia
• B7-H3 expressing tumor refers to a tumor which expresses B7-H3 protein.
• B7-H3 expression in a tumor is determined using immunohistochemical staining of tumor cell membranes, where any immunohistochemical staining above background level in a tumor sample indicates that the tumor is a B7-H3 expressing tumor.
• Methods for detecting expression of B7-H3 in a tumor are known in the art, and include immunohistochemical assays.
• a "B7-H3 negative tumor” is defined as a tumor having an absence of B7-H3 membrane staining above background in a tumor sample as determined by immunohistochemical techniques.
• overexpress refers to a gene that is transcribed or translated at a detectably greater level, usually in a cancer cell, in comparison to a normal cell. Overexpression therefore refers to both overexpression of protein and RNA (due to increased transcription, post transcriptional processing, translation, post translational processing, altered stability, and altered protein degradation), as well as local overexpression due to altered protein traffic patterns (increased nuclear localization), and augmented functional activity, e.g., as in an increased enzyme hydrolysis of substrate. Thus, overexpression refers to either protein or RNA levels. Overexpression can also be by 50%, 60%, 70%, 80%, 90% or more in comparison to a normal cell or comparison cell. In certain embodiments, the anti-B7-H3 antibodies or ADCs of the invention are used to treat solid tumors likely to overexpress B7-H3.
• gene amplification refers to a cellular process characterized by the production of multiple copies of any particular piece of DNA.
• a tumor cell may amplify, or copy, chromosomal segments as a result of cell signals and sometimes environmental events.
• the process of gene amplification leads to the production of additional copies of the gene.
• the gene is B7-H3, i.e., "B7-H3 amplification.”
• the compositions and methods disclosed herein are used to treat a subject having B7-H3 amplified cancer.
• administering is meant to refer to the delivery of a substance (e.g., an anti-B7-H3 antibody or ADC) to achieve a therapeutic objective (e.g. , the treatment of a B7-H3- associated disorder).
• Modes of administration may be parenteral, enteral and topical.
• Parenteral administration is usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.
• combination therapy refers to the administration of two or more therapeutic substances, e.g., an anti-B7-H3 antibody or ADC and an additional therapeutic agent.
• the additional therapeutic agent may be administered concomitant with, prior to, or following the administration of the anti-B7-H3 antibody or ADC.
• the term "effective amount” or “therapeutically effective amount” refers to the amount of a drug, e.g., an antibody or ADC, which is sufficient to reduce or ameliorate the severity and/or duration of a disorder, e.g., cancer, or one or more symptoms thereof, prevent the advancement of a disorder, cause regression of a disorder, prevent the recurrence, development, onset or progression of one or more symptoms associated with a disorder, detect a disorder, or enhance or improve the prophylactic or therapeutic effect(s) of another therapy (e.g. , prophylactic or therapeutic agent).
• a drug e.g., an antibody or ADC
• the effective amount of an antibody or ADC may, for example, inhibit tumor growth (e.g., inhibit an increase in tumor volume), decrease tumor growth (e.g., decrease tumor volume), reduce the number of cancer cells, and/or relieve to some extent one or more of the symptoms associated with the cancer.
• the effective amount may, for example, improve disease free survival (DFS), improve overall survival (OS), or decrease likelihood of recurrence.
• substituents are defined below.
• the number of carbon atoms in a substituent is indicated by the prefix “C x -C y " or "C x y " wherein x is the minimum and y is the maximum number of carbon atoms.
• C x -C y or "C x y " wherein x is the minimum and y is the maximum number of carbon atoms.
• Ci-Ce alkyl refers to an alkyl containing from 1 to 6 carbon atoms.
• C 3 -C 8 cycloalkyl means a saturated hydrocarbyl ring containing from 3 to 8 carbon ring atoms. If a substituent is described as being “substituted,” a hydrogen atom on a carbon or nitrogen is replaced with a non-hydrogen group.
• a substituted alkyl substituent is an alkyl substituent in which at least one hydrogen atom on the alkyl is replaced with a non-hydrogen group.
• monofluoroalkyl is alkyl substituted with a fluoro radical
• difluoroalkyl is alkyl substituted with two fluoro radicals.
• substituents include, but are not limited to, C C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, halogen, C C 6 haloalkyl, oxo, -CN, N0 2 , -OR xa , -OC(0)R xz , -OC(0)N(R xa ) 2 , -SR xa , -S(0) 2 R xa , -S(0) 2 N(R xa ) 2 , -C(0)R xa , -C(0)OR xa , -C(0)N(R xa ) 2 ,
• alkylenyl)-S(0) 2 R xa -(Q-C 6 alkylenyl)-S(0) 2 N(R xa ) 2 , -(Q-C 6 alkylenyl)-C(0)R xa , -(Q-C 6 alkylenyl)-C(0)OR xa , -(Q-Q alkylenyl)-C(0)N(R xa ) 2 , -(d-C 6 alkylenyl)-C(0)N(R xa )S(0) 2 R xz , -(d-C 6 alkylenyl)-N(R xa ) 2 , -(Q-Q, alkylenyl)-N(R xa )C(0)R xz , -(C C 6 alkylenyl)-N(R xa )S(0) 2 R xz , -(d-C 6 alkylenyl)-
• R x at each occurrence, is independently hydrogen, aryl, cycloalkyl, heterocyclyl, heteroaryl, d-d" alkyl, or d-d haloalkyl
• R xz at each occurrence, is independently aryl, cycloalkyl, heterocyclyl, heteroaryl, d-d alkyl or d-d haloalkyl.
• alkoxy refers to a group of the formula -OR x , where R x is an alkyl group.
• alkoxy groups include methoxy, ethoxy, propoxy, tert-butoxy and the like.
• alkoxyalkyl refers to an alkyl group substituted with an alkoxy group and may be represented by the general formula -R b OR x where R b is an alkylene group and R x is an alkyl group.
• alkyl by itself or as part of another substituent refers to a saturated or unsaturated branched, straight-chain or cyclic monovalent hydrocarbon radical that is derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane, alkene or alkyne.
• Typical alkyl groups include, but are not limited to, methyl; ethyls such as ethanyl, ethenyl, ethynyl; propyls such as propan-l-yl, propan-2-yl, cyclopropan-l-yl, prop-l-en-l-yl, prop-l-en-2-yl, prop-2-en-l-yl, cycloprop-l-en-l-yl; cycloprop-2-en-l-yl, prop-l-yn-l-yl , prop-2-yn-l-yl, etc.
• butyls such as butan-l-yl, butan-2-yl, 2-methyl-propan-l-yl, 2-methyl-propan-2-yl, cyclobutan-l-yl, but-l-en-l-yl, but-l-en-2-yl, 2-methyl-prop-l-en-l-yl, but-2-en-l-yl , but-2-en-2-yl, buta-l,3-dien-l-yl,
• alkanyl by itself or as part of another substituent refers to a saturated branched, straight-chain or cyclic alkyl derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane.
• Typical alkanyl groups include, but are not limited to, methyl; ethanyl; propanyls such as propan-l-yl, propan-2-yl (isopropyl), cyclopropan-l-yl, etc. ; butanyls such as butan-l-yl, butan-2-yl (sec-butyl), 2-methyl-propan-l-yl (isobutyl), 2-methyl-propan-2-yl (i-butyl),
• alkenyl by itself or as part of another substituent refers to an unsaturated branched, straight-chain or cyclic alkyl having at least one carbon-carbon double bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkene.
• Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop-l-en-l-yl , prop-l-en-2-yl, prop-2-en-l-yl, prop-2-en-2-yl, cycloprop-l-en-l-yl; cycloprop-2-en-l-yl ; butenyls such as but-l-en-l-yl, but-l-en-2-yl, 2-methyl-prop-l-en-l-yl, but-2-en-l-yl, but-2-en-2-yl,
• alkynyl by itself or as part of another substituent refers to an unsaturated branched, straight-chain or cyclic alkyl having at least one carbon-carbon triple bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkyne.
• Typical alkynyl groups include, but are not limited to, ethynyl; propynyls such as prop-l-yn-l-yl , prop-2-yn-l-yl, etc.; butynyls such as but-l-yn-l-yl, but-l-yn-3-yl, but-3-yn-l-yl , etc.; and the like.
• alkylamine refers to a group of the formula -NHR x and "dialkylamine” refers to a group of the formula -NR x R x , where each R x is, independently of the others, an alkyl group.
• alkylene refers to an alkane, alkene or alkyne group having two terminal monovalent radical centers derived by the removal of one hydrogen atom from each of the two terminal carbon atoms.
• Typical alkylene groups include, but are not limited to, methylene; and saturated or unsaturated ethylene; propylene; butylene; and the like.
• lower alkylene refers to alkylene groups with 1 to 6 carbons.
• heteroalkylene refers to a divalent alkylene having one or more -CH 2 - groups replaced with a thio, oxy, or -NR x3 - where R x3 is selected from hydrogen, lower alkyl and lower heteroalkyl.
• the heteroalkylene can be linear, branched, cyclic, bicyclic, or a combination thereof and can include up to 10 carbon atoms and up to 4 heteroatoms.
• lower heteroalkylene refers to alkylene groups with 1 to 4 carbon atoms and 1 to 3 heteroatoms.
• aryl means an aromatic carbocyclyl containing from 6 to 14 carbon ring atoms.
• An aryl may be monocyclic or poly cyclic (i.e., may contain more than one ring). In the case of poly cyclic aromatic rings, only one ring the poly cyclic system is required to be aromatic while the remaining ring(s) may be saturated, partially saturated or unsaturated. Examples of aryls include phenyl, naphthalenyl, indenyl, indanyl, and tetrahydronaphthyl.
• arylene refers to an aryl group having two monovalent radical centers derived by the removal of one hydrogen atom from each of the two ring carbons.
• An exemplary arylene group is a phenylene.
• alkyl group may be substituted by a "carbonyl” which means that two hydrogen atoms from a single alkanylene carbon atom are removed and replaced with a double bond to an oxygen atom.
• the prefix "halo" indicates that the substituent which includes the prefix is substituted with one or more independently selected halogen radicals.
• haloalkyl means an alkyl substituent in which at least one hydrogen radical is replaced with a halogen radical.
• Typical halogen radicals include chloro, fluoro, bromo and iodo.
• haloalkyls include chloromethyl, 1- bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, and 1,1,1-trifluoroethyl. It should be recognized that if a substituent is substituted by more than one halogen radical, those halogen radicals may be identical or different (unless otherwise stated).
• haloalkoxy refers to a group of the formula -OR c , where R c is a haloalkyl.
• heteroalkyl refers to any organic radical having the terms “heteroalkyl,” “heteroalkanyl,” “heteroalkenyl,” “heteroalkynyl,” and
• heteroalkylene refers to alkyl, alkanyl, alkenyl, alkynyl, and alkylene groups, respectively, in which one or more of the carbon atoms, e.g., 1, 2 or 3 carbon atoms, are each independently replaced with the same or different heteroatoms or heteroatomic groups.
• Typical heteroatoms and/or heteroatomic groups which can replace the carbon atoms include, but are not limited to, -0-, -S-, -S-0-, -NR C -, -PH, -S(O)-, -S(0) 2 -, -S(0)NR c -, -S(0) 2 NR c -, and the like, including combinations thereof, where each R c is independently hydrogen or C C 6 alkyl.
• the term "lower heteroalkyl” refers to between 1 and 4 carbon atoms and between 1 and 3 heteroatoms.
• cycloalkyl and “heterocyclyl” refer to cyclic versions of “alkyl” and
• heteroalkyl groups, respectively.
• a heteroatom can occupy the position that is attached to the remainder of the molecule.
• a cycloalkyl or heterocyclyl ring may be a single - ring (monocyclic) or have two or more rings (bicyclic or polycyclic).
• Monocyclic cycloalkyl and heterocyclyl groups will typically contains from 3 to 7 ring atoms, more typically from 3 to 6 ring atoms, and even more typically 5 to 6 ring atoms.
• Examples of cycloalkyl groups include, but are not limited to, cyclopropyl; cyclobutyls such as cyclobutanyl and cyclobutenyl; cyclopentyls such as cyclopentanyl and cyclopentenyl; cyclohexyls such as
• cyclohexanyl and cyclohexenyl examples include, but are not limited to, oxetane, furanyl, dihydrofuranyl, tetrahydrofuranyl, tetrahydropyranyl, thiophenyl (thiofuranyl), dihydrothiophenyl, tetrahydrothiophenyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, triazolyl, tetrazolyl, oxazolyl, oxazolidinyl, isoxazolidinyl, isoxazolidinyl, isoxazolidinyl, isoxazolyl, thiazolyl, isothiazolyl, thiazolinyl, isothiazoliny
• Polycyclic cycloalkyl and heterocyclyl groups contain more than one ring, and bicyclic cycloalkyl and heterocyclyl groups contain two rings. The rings may be in a bridged, fused or spiro orientation. Polycyclic cycloalkyl and heterocyclyl groups may include combinations of bridged, fused and/or spiro rings. In a spirocyclic cycloalkyl or heterocyclyl, one atom is common to two different rings.
• An example of a spirocycloalkyl is spiro[4.5]decane and an example of a
• spiroheterocyclyls is a spiropyrazoline.
• bridged cycloalkyl or heterocyclyl the rings share at least two common non-adjacent atoms.
• bridged cycloalkyls include, but are not limited to, adamantyl and norbornanyl rings.
• bridged heterocyclyls include, but are not limited to, 2- oxatricyclo [3.3.1.1 3 ' 7 ] decanyl.
• fused-ring cycloalkyl or heterocyclyl two or more rings are fused together, such that two rings share one common bond.
• fused-ring cycloalkyls include decalin, naphthylene, tetralin, and anthracene.
• fused-ring heterocyclyls containing two or three rings include imidazopyrazinyl (including imidazo[l,2-a]pyrazinyl), imidazopyridinyl (including imidazo[l,2- a]pyridinyl), imidazopyridazinyl (including imidazo[l,2-b]pyridazinyl), thiazolopyridinyl (including thiazolo[5,4-c]pyridinyl, thiazolo[5,4-b]pyridinyl, thiazolo[4,5-b]pyridinyl, and thiazolo[4,5- c]pyridinyl), indolizinyl, pyranopyrrolyl, 4H-quinolizinyl, purinyl, naphthyridinyl, pyridopyridinyl (including pyrido[3,4-b]-pyridinyl, pyrido[3,2-b
• fused-ring heterocyclyls include benzo-fused heterocyclyls, such as dihydrochromenyl, tetrahydroisoquinolinyl, indolyl, isoindolyl (isobenzazolyl, pseudoisoindolyl), indoleninyl (pseudoindolyl), isoindazolyl (benzpyrazolyl), benzazinyl (including quinolinyl (1- benzazinyl) or isoquinolinyl (2-benzazinyl)), phthalazinyl, quinoxalinyl, quinazolinyl, benzodiazinyl (including cinnolinyl (1,2-benzodiazinyl) or quinazolinyl (1,3-benzodiazinyl)), benzopyranyl (including chromanyl or isochromanyl), benzoxazinyl (including 1,3,2-benzoxazinyl, 1,
• cycloalkylene refers to a cycloalkyl group having two monovalent radical centers derived by the removal of one mplary cycloalkylene groups include:
• heteroaryl refers to an aromatic heterocyclyl containing from 5 to 14 ring atoms. A heteroaryl may be a single ring or 2 or 3 fused rings.
• heteroaryls include 6-membered rings such as pyridyl, pyrazyl, pyrimidinyl, pyridazinyl, and 1,3,5-, 1,2,4- or 1,2,3-triazinyl; 5- membered ring substituents such as triazolyl, pyrrolyl, imidazyl, furanyl, thiophenyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,3-, 1,2,4-, 1,2,5-, or 1,3,4-oxadiazolyl and isothiazolyl; 6/5- membered fused ring substituents such as imidazopyrazinyl (including imidazo[l,2- a] pyrazinyl)imidazopyridinyl (including imidazo[l,2-a]pyridinyl), imidazopyridazinyl (including imidazo[l,2-b]pyrida
• benzothiofuranyl benzisoxazolyl, benzoxazolyl, purinyl, and anthranilyl
• 6/6-membered fused rings such as benzopyranyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, and benzoxazinyl.
• Heteroaryls may also be heterocycles having aromatic (4N+2 pi electron) resonance contributors such as pyridonyl (including pyrid-2(lH)-onyl and pyrid-4(lH)-onyl), pyrimidonyl (including pyramid- 2(lH)-onyl and pyramid-4(3H)-onyl), pyridazin-3(2H)-onyl and pyrazin-2(lH)-onyl.
• aromatic (4N+2 pi electron) resonance contributors such as pyridonyl (including pyrid-2(lH)-onyl and pyrid-4(lH)-onyl), pyrimidonyl (including pyramid- 2(lH)-onyl and pyramid-4(3H)-onyl), pyridazin-3(2H)-onyl and pyrazin-2(lH)-onyl.
• sulfonate as used herein means a salt or ester of a sulfonic acid.
• methyl sulfonate as used herein means a methyl ester of a sulfonic acid group.
• carboxylate as used herein means a salt or ester of a carboxylic acid.
• polyol means a group containing more than two hydroxyl groups independently or as a portion of a monomer unit.
• Polyols include, but are not limited to, reduced C 2 - C 6 carbohydrates, ethylene glycol, and glycerin.
• sugar when used in context of “G 1 " includes O-glycoside, N-glycoside, 5- glycoside and C-glycoside (C-glycoslyl) carbohydrate derivatives of the monosaccharide and disaccharide classes and may originate from naturally-occurring sources or may be synthetic in origin.
• N-hydroxysuccinimide ester derivative of a carboxylic acid means the N-hydroxysuccinimide ester derivative of a carboxylic acid.
• amine includes primary, secondary and tertiary aliphatic amines, including cyclic versions.
• salt when used in context of "or salt thereof include salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases.
• these salts typically may be prepared by conventional means by reacting, for example, the appropriate acid or base with a compound of the invention
• the salt preferably is pharmaceutically acceptable and/or physiologically compatible.
• pharmaceutically acceptable is used adjectivally in this patent application to mean that the modified noun is appropriate for use as a pharmaceutical product or as a part of a pharmaceutical product.
• pharmaceutically acceptable salt includes salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. In general, these salts typically may be prepared by conventional means by reacting, for example, the appropriate acid or base with a compound of the invention.
• ADCs antibody drug conjugates comprising an anti-B7-H3 antibody described herein and at least one drug(s), such as, but not limited to, a Bcl-xL inhibitor or an auristatin.
• the antibodies or ADCs of the invention have characteristics including, but not limited to, binding to wild- type human B7-H3 in vitro, binding to wild-type human B7-H3 on tumor cells expressing B7-H3, and decreasing or inhibiting xenograft tumor growth in a mouse model.
• One aspect of the invention features an anti-human B7-H3 (anti-hB7-H3) Antibody Drug Conjugate (ADC) comprising an anti-hB7-H3 antibody conjugated to a drug via a linker, wherein the drug is a Bcl-xL inhibitor.
• ADC Antibody Drug Conjugate
• Exemplary anti-B7-H3 antibodies (and sequences thereof) that can be used in the ADCs are described herein.
• the anti-B7-H3 antibodies described herein provide the ADCs of the invention with the ability to bind to B7-H3 such that the cytotoxic Bcl-xL drug attached to the antibody may be delivered to the B7-H3-expressing cell, particularly a B7-H3 expressing cancer cell.
• antibody i.e., antigen-binding portions of an anti-B7-H3antibody
• an anti-B7-H3antibody fragment may be conjugated to the Bcl-xL inhibitors described herein.
• antibody fragments of the anti-B7- H3antibodies described herein are conjugated to Bcl-xL inhibitors (including those described below in Section III. A) via linkers (including those described below in Section III. A).
• the anti-B7-H3 antibody binding portion is a Fab, a Fab' , a F(ab')2, a Fv, a disulfide linked Fv, an scFv, a single domain antibody, or a diabody.
• a chimeric antibody is a molecule in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region.
• Methods for producing chimeric antibodies are known in the art. See e.g. , Morrison, Science 229: 1202 (1985); Oi et al , BioTechniques 4:214 (1986); Gillies et al, (1989) /. Immunol. Methods 125: 191-202; U.S. Pat. Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entireties.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable region including an amino acid sequence set forth in SEQ ID NOs: 1, 9, 16, 24, 32, 40, 48, 56, 64, 72, 80, 87, 95, 101, or 108; and/or a light chain variable region including an amino acid sequence set forth in SEQ ID NOs: 5, 13, 20, 28, 36, 44, 52, 60, 68, 76, 84, 91, 98, 105, or 112.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 1, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 5.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 2; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 3; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 4; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 6; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 8.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 9, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 13.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 11 ; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 14 (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 16, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 20.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 17; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 18; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 19; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 21 ; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 22; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 23.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 24, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 28.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 25; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 26; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 27; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 29; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 30; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 31.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 32, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 36.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 33; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 34; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 35; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 37; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 38; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 182.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 40, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 44.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 41 ; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 42; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 43; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 45; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 46; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 47.
• a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 41 ; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 42; and (c) a C
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 48, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 52.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 49; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 50; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 51 ; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 53; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 54; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 55.
• a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 49; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 50; and (c) a CDR
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 56, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 60.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 57; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 58; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 59; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 61 ; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 62; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 63.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 64, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 68.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 65; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 66; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 67; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 69; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 70; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 71.
• a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 65; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 66; and (c)
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 72, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 76.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 73; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 74; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 75; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 77; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 78; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 79.
• a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 73; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 74; and (
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 80, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 84.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 81 ; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 82; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 83; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 85; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 86.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 87, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 91.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 88; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 89; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 90; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 92; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 93; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 94.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 95, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 98.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 49; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 96; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 97; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 99; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 93; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 100.
• a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 49; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 96; and (c)
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 101, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 105.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 102; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 103; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 104; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 106; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 46; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 107.
• a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 102; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 103; and (
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 108, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 112.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 109; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 110; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 111 ; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 113; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 114; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 115.
• a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 109; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 110; and (
• chimeric antibodies disclosed herein may be used in the production of humanized anti- B7-H3 antibodies.
• chAbl-chAbl8 antibodies chAb3, chAbl3, and chAbl8 were selected for
• huAb3vl six different humanized antibodies were created based on chAb3 (referred to herein as huAb3vl, huAb3v2, huAb3v3, huAb3v4, huAb3v5, and huAb3v6 (see
• humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and framework regions from a human immunoglobulin molecule.
• CDRs complementarity determining regions
• Known human Ig sequences are disclosed, e.g. , www.ncbi.nlm.nih.gov/entrez- /query.fcgi;
• Framework residues in the human framework regions may be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, antigen binding.
• These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g. , Queen et al, U.S. Pat. No. 5,585,089; Riechmann et al, Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art.
• Antibodies can be humanized using a variety of techniques known in the art, such as but not limited to those described in Jones et al, Nature 321 :522 (1986); Verhoeyen et al , Science 239: 1534 (1988)), Sims et al , ]. Immunol. 151 : 2296 (1993); Chothia and Lesk, J. Mol. Biol. 196:901 (1987), Carter et al , Proc. Natl. Acad. Sci. U.S.A. 89:4285 (1992); Presta et al, J. Immunol.
• huAb3vl VH amino acid sequence set forth in SEQ ID NO: 125 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 10, 11, and 12, respectively; and VL amino acid sequence set forth in SEQ ID NO: 128 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 14, 7, and 15, respectively;
• huAb3v2 VH amino acid sequence set forth in SEQ ID NO: 127 and VH CDR1 , CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 10, 11, and 12, respectively; and VL amino acid sequence set forth in SEQ ID NO: 128 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 14, 7, and 15, respectively;
• huAb3v3 VH amino acid sequence set forth in SEQ ID NO: 126 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 10, 11, and 12, respectively; and VL amino acid sequence set forth in SEQ ID NO: 129 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 14, 7, and 15, respectively;
• huAb3v4 VH amino acid sequence set forth in SEQ ID NO: 125 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 10, 11, and 12, respectively; and VL amino acid sequence set forth in SEQ ID NO: 130 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 14, 7, and 15, respectively;
• huAb3v5 VH amino acid sequence set forth in SEQ ID NO: 127 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 10, 11, and 12, respectively; and VL amino acid sequence set forth in SEQ ID NO: 130 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 14, 7, and 15, respectively; and
• huAb3v6 VH amino acid sequence set forth in SEQ ID NO: 126 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 10, 11, and 12, respectively; and VL amino acid sequence set forth in SEQ ID NO: 130 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 14, 7, and 15, respectively.
• huAb3v2 was selected for further modified in order to remove potential deamidation or isomerization sites in the light chain CDR1 or in the heavy chain CDR2.
• huAb3v2 Nine variants of the humanized antibody huAb3v2 were generated, and are referred to herein as huAb3v2.1, huAb3v2.2, huAb3v2.3, huAb3v2.4, huAb3v2.5, huAb3v2.6, huAb3v2.7, huAb3v2.8, and huAb3v2.9 (CDR and variable domain sequences are provided in Table 16).
• the nine variants of the huAb3v2 antibody include the following:
• huAb3v2.1 VH amino acid sequence set forth in SEQ ID NO: 131 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 10, 132, and 12, respectively; and VL amino acid sequence set forth in SEQ ID NO: 133 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 134, 7, and 15, respectively;
• huAb3v2.2 VH amino acid sequence set forth in SEQ ID NO: 131 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 10, 132, and 12, respectively; and VL amino acid sequence set forth in SEQ ID NO: 135 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 136, 7, and 15, respectively;
• huAb3v2.4 VH amino acid sequence set forth in SEQ ID NO: 139 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 10, 140, and 12, respectively; and VL amino acid sequence set forth in SEQ ID NO: 133 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 134, 7, and 15, respectively;
• huAb3v2.5 VH amino acid sequence set forth in SEQ ID NO: 139 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 10, 140, and 12, respectively; and VL amino acid sequence set forth in SEQ ID NO: 135 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 136, 7, and 15, respectively;
• huAb3v2.6 VH amino acid sequence set forth in SEQ ID NO: 139 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 10, 140, and 12, respectively; and VL amino acid sequence set forth in SEQ ID NO: 137 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 138, 7, and 15, respectively;
• H huAb3v2.8 (VH amino acid sequence set forth in SEQ ID NO: 141 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 10, 142, and 12, respectively; and VL amino acid sequence set forth in SEQ ID NO: 135 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 136, 7, and 15, respectively); and
• huAb3v2.9 VH amino acid sequence set forth in SEQ ID NO: 141 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 10, 142, and 12, respectively; and VL amino acid sequence set forth in SEQ ID NO: 137 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 138, 7, and 15, respectively.
• the present invention provides antibodies comprising variable and/or
• the invention features anti-B7-H3 antibodies which are derived from Ab3 have improved characteristics, e.g., improved binding affinity to isolated B7-H3 protein and improved binding to B7-H3 expressing cells, as described in the Examples below. Collectively these novel antibodies are referred to herein as "Ab3 variant antibodies.” Generally, the Ab3 variant antibodies retain the same epitope specificity as Ab3. In various embodiments, anti-B7-H3 antibodies, or antigen binding fragments thereof, of the invention are capable of modulating a biological function of B7-H3.
• the present invention provides a humanized antibody, or antigen binding portion thereof, having a heavy chain variable region including an amino acid sequence set forth in SEQ ID NOs: 125, 126, 127, 131, 139, or 141 ; and/or a light chain variable region including an amino acid sequence set forth in SEQ ID NOs: 128, 129, 130, 133, 135, or 137.
• the present invention is directed to an anti-B7-H3 antibody, or antigen binding portion thereof, of the invention comprises a heavy chain variable region comprising a CDR1 domain comprising an amino acid sequence as set forth in SEQ ID NO: 10; a CDR2 domain comprising an amino acid sequence as set forth in SEQ ID NO: 11, 132, 140, or 142; and a CDR3 domain comprising an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region comprising a CDR1 domain comprising an amino acid sequence as set forth in SEQ ID NO:
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 125, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 128.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 127, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 128.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 126, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 129.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 125, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 130.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 127, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 130.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 126, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 130.
• the present invention is directed to a humanized anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 11 ; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 14; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 131, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 133.
• the present invention is directed to a humanized anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 132; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 134; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 131, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 135.
• the present invention is directed to a humanized anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 132; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 136; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 131, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 137.
• the present invention is directed to a humanized anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 132; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 138; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 139, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 133.
• the present invention is directed to a humanized anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 140; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 134; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 139, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 135.
• the present invention is directed to a humanized anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 140; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 136; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain comprising the amino acid sequence of SEQ ID NO: 170 and a light chain comprising the amino acid sequence of SEQ ID NO: 171.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 139, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 137.
• the present invention is directed to a humanized anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 140; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 138; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the present invention is directed to an anti-B7-H3 antibody, or antigen- binding portion thereof, having a heavy chain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain comprising the amino acid sequence of SEQ ID NO: 173.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 141, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 133.
• the present invention is directed to a humanized anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 142; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 134; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 141, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 135.
• the present invention is directed to a humanized anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 142; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 136; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 141, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 137.
• the present invention is directed to a humanized anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 142; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 138; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the nine different humanized antibodies created based on chAbl3 include the following:
• huAbl3vl VH amino acid sequence set forth in SEQ ID NO: 147 and VH CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 33, 34, and 35, respectively; and VL amino acid sequence set forth in SEQ ID NO: 144 and VL CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 37, 38, and 39, respectively;
• huAbl3v2 VH amino acid sequence set forth in SEQ ID NO: 146 and VH CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 33, 34, and 35, respectively; and VL amino acid sequence set forth in SEQ ID NO: 143 and VL CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 37, 38, and 39, respectively;
• huAbl3v3 VH amino acid sequence set forth in SEQ ID NO: 146 and VH CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 33, 34, and 35, respectively; and VL amino acid sequence set forth in SEQ ID NO: 144 and VL CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 37, 38, and 39, respectively;
• huAbl3v4 VH amino acid sequence set forth in SEQ ID NO: 146 and VH CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 33, 34, and 35, respectively; and VL amino acid sequence set forth in SEQ ID NO: 145 and VL CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 37, 38, and 39, respectively;
• huAbl3v5 VH amino acid sequence set forth in SEQ ID NO: 147 and VH CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 33, 34, and 35, respectively; and VL amino acid sequence set forth in SEQ ID NO: 143 and VL CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 37, 38, and 39, respectively;
• huAbl3v6 VH amino acid sequence set forth in SEQ ID NO: 147 and VH CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 33, 34, and 35, respectively; and VL amino acid sequence set forth in SEQ ID NO: 145 and VL CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 37, 38, and 39, respectively;
• huAbl3v7 VH amino acid sequence set forth in SEQ ID NO: 148 and VH CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 33, 34, and 35, respectively; and VL amino acid sequence set forth in SEQ ID NO: 143 and VL CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 37, 38, and 39, respectively;
• H huAbl3v8 (VH amino acid sequence set forth in SEQ ID NO: 148 and VH CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 33, 34, and 35, respectively; and VL amino acid sequence set forth in SEQ ID NO: 144 and VL CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 37, 38, and 39, respectively);
• huAbl3v9 VH amino acid sequence set forth in SEQ ID NO: 148 and VH CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 33, 34, and 35, respectively; and VL amino acid sequence set forth in SEQ ID NO: 145 and VL CDRl, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 37, 38, and 39, respectively.
• the present invention provides antibodies comprising variable and/or CDR sequences from a humanized antibody derived from chAbl3.
• the invention features anti-B7-H3 antibodies which are derived from chAbl3 have improved characteristics, e.g., improved binding affinity to isolated B7-H3 protein and improved binding to B7-H3 expressing cells, as described in the Examples below. Collectively these novel antibodies are referred to herein as "Abl3 variant antibodies.” Generally, the Abl3 variant antibodies retain the same epitope specificity as Abl3.
• anti-B7-H3 antibodies, or antigen binding fragments thereof, of the invention are capable of modulating a biological function of B7-H3.
• the present invention provides a humanized antibody, or antigen binding portion thereof, having a heavy chain variable region including an amino acid sequence set forth in SEQ ID NOs: 146, 147, or 148; and/or a light chain variable region including an amino acid sequence set forth in SEQ ID NOs: 143, 144, or 145.
• the present invention is directed to an anti-B7-H3 antibody, or antigen binding portion thereof, of the invention comprises a heavy chain variable region comprising a CDR1 domain comprising an amino acid sequence as set forth in SEQ ID NO: 33; a CDR2 domain comprising an amino acid sequence as set forth in SEQ ID NO: 34; and a CDR3 domain comprising an amino acid sequence as set forth in SEQ ID NO: 35; and a light chain variable region comprising a CDR1 domain comprising an amino acid sequence as set forth in SEQ ID NO: 37; a CDR2 domain comprising an amino acid sequence as set forth in SEQ ID NO: 38; and a CDR3 domain comprising an amino acid sequence as set forth in SEQ ID NO: 39.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 147, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 144.
• the invention provides an anti-B7H3 antibody comprising the CDR sequences set forth in the variable regions of huAbl3vl (SEQ ID NOs. 144 and 147).
• the present invention is directed to an anti-B7-H3 antibody, or antigen binding portion thereof, having a heavy chain comprising the amino acid sequence of SEQ ID NO: 168 and a light chain comprising the amino acid sequence of SEQ ID NO: 169.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 146, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 143.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 146, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 144.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 146, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 145.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 147, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 143.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 147, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 145.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 148, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 143.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 148, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 144.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 148, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 145.
• the ten different humanized antibodies created based on chAbl8 include the following:
• huAbl8vl VH amino acid sequence set forth in SEQ ID NO: 116 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 25, 26, and 27, respectively; and VL amino acid sequence set forth in SEQ ID NO: 120 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively;
• huAbl8v2 VH amino acid sequence set forth in SEQ ID NO: 118 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 25, 119, and 27, respectively; and VL amino acid sequence set forth in SEQ ID NO: 120 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively;
• huAbl8v3 VH amino acid sequence set forth in SEQ ID NO: 117 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 25, 26, and 27, respectively; and VL amino acid sequence set forth in SEQ ID NO: 121 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively;
• huAbl8v4 VH amino acid sequence set forth in SEQ ID NO: 118 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 25, 119, and 27, respectively; and VL amino acid sequence set forth in SEQ ID NO: 121 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively;
• huAbl8v5 VH amino acid sequence set forth in SEQ ID NO: 116 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 25, 26, and 27, respectively; and VL amino acid sequence set forth in SEQ ID NO: 123 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively;
• huAbl8v6 VH amino acid sequence set forth in SEQ ID NO: 118 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 25, 119, and 27, respectively; and VL amino acid sequence set forth in SEQ ID NO: 123 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively;
• huAbl8v7 VH amino acid sequence set forth in SEQ ID NO: 118 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 25, 119, and 27, respectively; and VL amino acid sequence set forth in SEQ ID NO: 124 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively;
• H huAbl8v8 (VH amino acid sequence set forth in SEQ ID NO: 117 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 25, 26, and 27, respectively; and VL amino acid sequence set forth in SEQ ID NO: 122 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively);
• huAbl8v9 VH amino acid sequence set forth in SEQ ID NO: 117 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 25, 26, and 27, respectively; and VL amino acid sequence set forth in SEQ ID NO: 124 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively; and
• huAbl8vl0 VH amino acid sequence set forth in SEQ ID NO: 118 and VH CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 25, 119, and 27, respectively; and VL amino acid sequence set forth in SEQ ID NO: 122 and VL CDR1, CDR2, and CDR3 amino acid sequences set forth in SEQ ID NOs: 29, 30, and 31, respectively.
• the present invention provides antibodies comprising variable and/or CDR sequences from a humanized antibody derived from chAbl8.
• the invention features anti-B7-H3 antibodies which are derived from Abl8 have improved characteristics, e.g., improved binding affinity to isolated B7-H3 protein and improved binding to B7-H3 expressing cells, as described in the Examples below. Collectively these novel antibodies are referred to herein as
• Abl8 variant antibodies Generally, the Abl8 variant antibodies retain the same epitope specificity as Abl8.
• anti-B7-H3 antibodies, or antigen binding fragments thereof, of the invention are capable of modulating a biological function of B7-H3.
• the present invention provides a humanized antibody, or antigen binding portion thereof, having a heavy chain variable region including an amino acid sequence set forth in SEQ ID NOs: 116, 117, or 118; and/or a light chain variable region including an amino acid sequence set forth in SEQ ID NOs: 120, 121, 122, 123 or 124.
• the present invention is directed to an anti-B7-H3 antibody, or antigen binding portion thereof, of the invention comprises a heavy chain variable region comprising a CDR1 domain comprising an amino acid sequence as set forth in SEQ ID NO: 25; a CDR2 domain comprising an amino acid sequence as set forth in SEQ ID NO: 26 or 119; and a CDR3 domain comprising an amino acid sequence as set forth in SEQ ID NO: 27; and a light chain variable region comprising a CDR1 domain comprising an amino acid sequence as set forth in SEQ ID NO: 29; a CDR2 domain comprising an amino acid sequence as set forth in SEQ ID NO: 30; and a CDR3 domain comprising an amino acid sequence as set forth in SEQ ID NO: 31.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 116, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 120.
• the present invention is directed to a humanized anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 25; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 26; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 27; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 29; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 30; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 31.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 118, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 120.
• the present invention is directed to a humanized anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 25; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 119; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 27; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 29; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 30; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 31.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 117, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 121.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 118, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 121.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 116, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 123.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 118, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 123.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 118, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 124.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 117, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 122.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 117, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 124.
• the present invention is directed to an anti-B7-H3 antibody, or antigen-binding portion thereof, having a heavy chain variable region including an amino acid sequence as set forth in SEQ ID NO: 118, and a light chain variable region including an amino acid sequence set forth in SEQ ID NO: 122.
• the present invention provides a humanized antibody, or antigen binding portion thereof, having a heavy chain variable region including an amino acid sequence set forth in SEQ ID NOs: 116, 117, 118, 146, 147, 148, 125, 126, 127, 131, 139, or 141; and/or a light chain variable region including an amino acid sequence set forth in SEQ ID NOs: 120, 121, 122, 123, 124, 143, 144, 145, 128, 129, 130, 133, 135, or 137.
• the present invention is directed to an anti-B7-H3 antibody, or antigen binding portion thereof, of the invention comprises a heavy chain variable region comprising a CDR1 domain comprising an amino acid sequence as set forth in SEQ ID NO: 10, 25, or 33; a CDR2 domain comprising an amino acid sequence as set forth in SEQ ID NO: 11, 26, 34, 119, 132, 140, or 142; and a CDR3 domain comprising an amino acid sequence as set forth in SEQ ID NO: 12, 27, or 35; and a light chain variable region comprising a CDR1 domain comprising an amino acid sequence as set forth in SEQ ID NO: 14, 29, 37, 134, 136, or 138; a CDR2 domain comprising an amino acid sequence as set forth in SEQ ID NO: 7, 30, or 38; and a CDR3 domain comprising an amino acid sequence as set forth in SEQ ID NO: 15, 31 or 39.
• the invention provides an anti-B7-H3 antibody, or antigen binding fragment thereof, that specifically competes with an anti-B7-H3 antibody, or fragment thereof, as described herein, wherein said competition can be detected in a competitive binding assay using said antibody, the human B7-H3 polypeptide, and the anti-B7-H3 antibody or fragment thereof.
• the competing antibody, or antigen binding portion thereof is an antibody, or antigen binding portion thereof, that competes with huAb3v2.5, huAb3v2.6, or huAbl3vl.
• the anti-B7-H3 antibodies, or antigen binding portions thereof, of the invention bind to the extracellular domain of human B7-H3 (SEQ ID NO: 152) with a dissociation constant (K D ) of about 1 x 10 6 M or less, as determined by surface plasmon resonance.
• the antibodies, or antigen binding portions thereof bind to human B7-H3 with a K D of between about 1 x 10 6 M and about 1 x 10 11 M, as determined by surface plasmon resonance.
• antibodies, or antigen binding portions thereof bind to human B7-H3 with a K D of between about 1 x 10 6 M and about 1 x 10 7 M, as determined by surface plasmon resonance.
• antibodies, or antigen binding portions thereof, of the invention binds to human B7-H3 with a K D of between about 1 x 10 6 M and about 5 x 10 11 M, about 1 x 10 6 M and about 5 x 10 10 M; a K D of between about 1 x 10 6 M and about 1 x 10 9 M; a K D of between about 1 x 10 6 M and about 5 x 10 9 M; a K D of between about 1 x 10 6 M and about 1 x 10 8 M; a K D of between about 1 x 10 6 M and about 5 x 10 8 M; a K D of between about 1 x 10 7 M and about 3.4 x 10 11 M; a K D of between about 5.9 x 10 7 M; and about 2.2 x 10 7 M, as determined by surface plasmon resonance.
• the antibodies, or antigen binding portions thereof, of the invention bind to human B7-H3 (SEQ ID NO: 149) with a K D of about 1 x 10 6 M or less, as determined by surface plasmon resonance.
• the antibodies, or antigen binding portions thereof, of the invention bind to human B7-H3 (SEQ ID NO: 149) with a K D of between about 8.2 x 10 9 M and about 6.3 x 10 10 M; a K D of between about 8.2 x 10 9 M and about 2.0 x 10 9 M; a K D of between about 2.3 x 10 9 M and about 1.5 x 10 10 M, as determined by surface plasmon resonance.
• the foregoing establish a novel family of B7-H3 binding proteins, isolated in accordance with this invention, and including antigen binding polypeptides that comprise the CDR sequences listed in the Sequence Table provided herein.
• Anti-B7-H3 antibodies provided herein may comprise a heavy chain variable region comprising CDR1, CDR2 and CDR3 sequences and a light chain variable region comprising CDR1, CDR2 and CDR3 sequences, wherein one or more of these CDR sequences comprise specified amino acid sequences based on the antibodies described herein (e.g., huAbl3vl or huAb3v2.5), or conservative modifications thereof, and wherein the antibodies retain the desired functional properties of the anti-B7-H3antibodies described herein.
• the anti-B7-H3 antibody, or antigen binding portion thereof may comprise a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences, wherein: (a) the heavy chain variable region CDR3 sequence comprises SEQ ID NO: 12 or 35, and conservative modifications thereof, e.g., 1, 2, 3, 4, 5, 1-2, 1-3, 1-4 or 1-5 conservative amino acid substitutions; (b) the light chain variable region CDR3 sequence comprises SEQ ID NO: 15 or 39, and conservative modifications thereof, e.g., 1, 2, 3, 4, 5, 1-2, 1-3, 1-4 or 1-5 conservative amino acid substitutions; (c) the antibody specifically binds to B7-H3, and (d) the antibody exhibits 1, 2, 3, 4, 5, 6, or all of the following functional properties described herein, e.g., binding to soluble human B7-H3.
• the heavy chain variable region CDR3 sequence comprises SEQ ID NO: 12 or 35, and conservative modifications thereof
• the heavy chain variable region CDR2 sequence comprises SEQ ID NO: 140 or 34, and conservative modifications thereof, e.g., 1, 2, 3, 4, 5, 1-2, 1-3, 1-4 or 1-5 conservative amino acid substitutions; and the light chain variable region CDR2 sequence comprises SEQ ID NO: 7 or 38, and conservative modifications thereof, e.g., 1, 2, 3, 4, 5, 1-2, 1-3, 1-4 or 1-5 conservative amino acid substitutions.
• the heavy chain variable region CDR1 sequence comprises SEQ ID NO: 10 or 33, and conservative modifications thereof, e.g., 1, 2, 3, 4, 5, 1-2, 1-3, 1-4 or 1-5 conservative amino acid substitutions; and the light chain variable region CDR1 sequence comprises SEQ ID NO: 136, 138, or 37, and conservative modifications thereof, e.g., 1, 2, 3, 4, 5, 1-2, 1-3, 1-4 or 1-5 conservative amino acid substitutions.
• Conservative amino acid substitutions may also be made in portions of the antibodies other than, or in addition to, the CDRs.
• conservative amino acid modifications may be made in a framework region or in the Fc region.
• a variable region or a heavy or light chain may comprise 1 , 2, 3, 4, 5, 1-2, 1-3, 1-4, 1-5, 1-10, 1-15, 1-20, 1-25, or 1-50 conservative amino acid substitutions relative to the anti-B7-H3 antibody sequences provided herein.
• the anti-B7- H3antibody comprises a combination of conservative and non-conservative amino acid modification.
• the antibody comprises a heavy chain constant region, such as an IgGl, IgG2, IgG3, IgG4, IgA, IgE, IgM, or IgD constant region.
• the anti-B7- H3 antibody, or antigen binding portion thereof comprises a heavy chain immunoglobulin constant domain selected from the group consisting of a human IgG constant domain, a human IgM constant domain, a human IgE constant domain, and a human IgA constant domain.
• the antibody, or antigen binding portion thereof has an IgGl heavy chain constant region, an IgG2 heavy chain constant region, an IgG3 constant region, or an IgG4 heavy chain constant region.
• the heavy chain constant region is an IgGl heavy chain constant region or an IgG4 heavy chain constant region.
• the antibody can comprise a light chain constant region, either a kappa light chain constant region or a lambda light chain constant region.
• the antibody comprises a kappa light chain constant region.
• the antibody portion can be, for example, a Fab fragment or a single chain Fv fragment.
• the anti-B7-H3 antibody binding portion is a Fab, a Fab' , a F(ab')2, a
• Fv a disulfide linked Fv, an scFv, a single domain antibody, or a diabody.
• the anti-B7-H3 antibody, or antigen binding portion thereof is a multispecific antibody, e.g. a bispecific antibody.
• the Fc portion of an antibody mediates several important effector functions e.g. cytokine induction, ADCC, phagocytosis, complement dependent cytotoxicity (CDC) and half -life/ clearance rate of antibody and antigen-antibody complexes. In some cases these effector functions are desirable for therapeutic antibody but in other cases might be unnecessary or even deleterious, depending on the therapeutic objectives.
• Neonatal Fc receptors are the critical components determining the circulating half-life of antibodies.
• at least one amino acid residue is replaced in the constant region of the antibody, for example the Fc region of the antibody, such that effector functions of the antibody are altered.
• One embodiment of the invention includes a recombinant chimeric antigen receptor (CAR) comprising the binding regions of the antibodies described herein, e.g., the heavy and/or light chain CDRs of huAbl3vl.
• a recombinant CAR, as described herein, may be used to redirect T cell specificity to an antigen in a human leukocyte antigen (HL A) -independent fashion.
• CARs of the invention may be used in immunotherapy to help engineer a human subject's own immune cells to recognize and attack the subject's tumor (see, e.g., U.S. Pat. Nos. 6,410,319; 8,389,282; 8,822,647;
• This type of immunotherapy is called adoptive cell transfer (ACT), and may be used to treat cancer in a subject in need thereof.
• ACT adoptive cell transfer
• An anti-B7-H3 CAR of the invention preferably contains a extracellular antigen-binding domain specific for B7-H3, a transmembrane domain which is used to anchor the CAR into a T cell, and one or more intracellular signaling domains.
• the CAR includes a transmembrane domain that comprises a transmembrane domain of a protein selected from the group consisting of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154.
• the CAR comprises a costimulatory domain, e.g., a costimulatory domain comprising a functional signaling domain of a protein selected from the group consisting of OX40, CD2, CD27, CD28, CD5, ICAM-1, LFA-1 (CDl la/CD18), ICOS (CD278), and 4-1BB (CD137).
• a costimulatory domain comprising a functional signaling domain of a protein selected from the group consisting of OX40, CD2, CD27, CD28, CD5, ICAM-1, LFA-1 (CDl la/CD18), ICOS (CD278), and 4-1BB (CD137).
• the CAR comprises an scFv comprising the CDR or variable regions described herein e.g., CDRs or variable regions from the huAbl3vl antibody, a transmembrane domain, a co-stimulatory domain (e.g., a functional signaling domain from CD28 or 4-1BB), and a signaling domain comprising a functional signaling domain from CD3 (e.g., CD3-zeta).
• scFv comprising the CDR or variable regions described herein e.g., CDRs or variable regions from the huAbl3vl antibody, a transmembrane domain, a co-stimulatory domain (e.g., a functional signaling domain from CD28 or 4-1BB), and a signaling domain comprising a functional signaling domain from CD3 (e.g., CD3-zeta).
• the invention incudes a T cell comprising a CAR (also referred to as a CAR T cell) comprising antigen binding regions, e.g. CDRs, of the antibodies described herein or an scFv described herein.
• a CAR also referred to as a CAR T cell
• antigen binding regions e.g. CDRs, of the antibodies described herein or an scFv described herein.
• the CAR comprises a heavy chain variable region comprising a CDRl domain comprising an amino acid sequence as set forth in SEQ ID NO: 10, 25, or 33; a CDR2 domain comprising an amino acid sequence as set forth in SEQ ID NO: 11, 26, 34, 119, 132, 140, or 142; and a CDR3 domain comprising an amino acid sequence as set forth in SEQ ID NO: 12, 27, or 35; and a light chain variable region comprising a CDRl domain comprising an amino acid sequence as set forth in SEQ ID NO: 14, 29, 37, 134, 136, or 138; a CDR2 domain comprising an amino acid sequence as set forth in SEQ ID NO: 7, 30, or 38; and a CDR3 domain comprising an amino acid sequence as set forth in SEQ ID NO: 15, 31 or 39.
• the CAR comprises a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 11 ; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 14; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the CAR comprises a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 132; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 134; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the CAR comprises a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 132; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 136; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the CAR comprises a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 132; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 138; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the CAR comprises a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 140; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 134; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the CAR comprises a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 140; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 136; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the CAR comprises a heavy chain variable domain region including (a) a CDRl having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 140; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 138; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the CAR comprises a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 142; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 134; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the CAR comprises a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 142; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 136; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the CAR comprises a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 10; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 142; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 12; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 138; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 7; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 15.
• the CAR comprises a heavy chain variable region comprising a CDR1 domain comprising an amino acid sequence as set forth in SEQ ID NO: 33; a CDR2 domain comprising an amino acid sequence as set forth in SEQ ID NO: 34; and a CDR3 domain comprising an amino acid sequence as set forth in SEQ ID NO: 35; and a light chain variable region comprising a CDR1 domain comprising an amino acid sequence as set forth in SEQ ID NO: 37; a CDR2 domain comprising an amino acid sequence as set forth in SEQ ID NO: 38; and a CDR3 domain comprising an amino acid sequence as set forth in SEQ ID NO: 39.
• the CAR comprises a heavy chain variable region comprising a CDR1 domain comprising an amino acid sequence as set forth in SEQ ID NO: 25; a CDR2 domain comprising an amino acid sequence as set forth in SEQ ID NO: 26 or 119; and a CDR3 domain comprising an amino acid sequence as set forth in SEQ ID NO: 27; and a light chain variable region comprising a CDR1 domain comprising an amino acid sequence as set forth in SEQ ID NO: 29; a CDR2 domain comprising an amino acid sequence as set forth in SEQ ID NO: 30; and a CDR3 domain comprising an amino acid sequence as set forth in SEQ ID NO: 31.
• the CAR comprises a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 25; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 26; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 27; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 29; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 30; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 31.
• the CAR comprises a heavy chain variable domain region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 25; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 119; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 27; and a light chain variable region including (a) a CDR1 having an amino acid sequence as set forth in SEQ ID NO: 29; (b) a CDR2 having an amino acid sequence as set forth in SEQ ID NO: 30; and (c) a CDR3 having an amino acid sequence as set forth in SEQ ID NO: 31.
• One embodiment of the invention includes a labeled anti-B7-H3 antibody, or antibody portion thereof, where the antibody is derivatized or linked to one or more functional molecule(s) (e.g. , another peptide or protein).
• a labeled antibody can be derived by functionally linking an antibody or antibody portion of the invention (by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody (e.g.
• a bispecific antibody or a diabody a detectable agent, a pharmaceutical agent, a protein or peptide that can mediate the association of the antibody or antibody portion with another molecule (such as a streptavidin core region or a polyhistidine tag), and/or a cytotoxic or therapeutic agent selected from the group consisting of a mitotic inhibitor, an antitumor antibiotic, an immunomodulating agent, a vector for gene therapy, an alkylating agent, an antiangiogenic agent, an antimetabolite, a boron- containing agent, a chemoprotective agent, a hormone, an antihormone agent, a corticosteroid, a photoactive therapeutic agent, an oligonucleotide, a radionuclide agent, a topoisomerase inhibitor, a kinase inhibitor, a radiosensitizer, and a combination thereof.
• a mitotic inhibitor an antitumor antibiotic
• an immunomodulating agent a vector for gene therapy, an
• Useful detectable agents with which an antibody or antibody portion thereof, may be derivatized include fluorescent compounds.
• Exemplary fluorescent detectable agents include fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine-l-napthalenesulfonyl chloride, phycoerythrin and the like.
• An antibody may also be derivatized with detectable enzymes, such as alkaline phosphatase, horseradish peroxidase, glucose oxidase and the like. When an antibody is derivatized with a detectable enzyme, it is detected by adding additional reagents that the enzyme uses to produce a detectable reaction product.
• the detectable agent horseradish peroxidase when the detectable agent horseradish peroxidase is present the addition of hydrogen peroxide and diaminobenzidine leads to a colored reaction product, which is detectable.
• An antibody may also be derivatized with biotin, and detected through indirect measurement of avidin or streptavidin binding.
• the antibody of the invention is conjugated to an imaging agent.
• imaging agents examples include, but are not limited to, a radiolabel (e.g., indium), an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, and biotin.
• the antibodies or ADCs are linked to a radiolabel, such as, but not limited to, indium ( m In).
• m Indium may be used to label the antibodies and ADCs described herein for use in identifying B7-H3 positive tumors.
• anti-B7-H3 antibodies (or ADCs) described herein are labeled with m I via a bifunctional chelator which is a bifunctional cyclohexyl diethylenetriaminepentaacetic acid (DTP A) chelate (see US Patent Nos. 5,124,471 ; 5,434,287; and 5,286,850, each of which is incorporated herein by reference).
• DTP A bifunctional cyclohexyl diethylenetriaminepentaacetic acid
• Another embodiment of the invention provides a glycosylated binding protein wherein the anti-B7-H3 antibody or antigen binding portion thereof comprises one or more carbohydrate residues.
• Nascent in vivo protein production may undergo further processing, known as post-translational modification.
• sugar (glycosyl) residues may be added enzymatically, a process known as glycosylation.
• glycosylation The resulting proteins bearing covalently linked oligosaccharide side chains are known as glycosylated proteins or glycoproteins.
• Antibodies are glycoproteins with one or more carbohydrate residues in the Fc domain, as well as the variable domain.
• Carbohydrate residues in the Fc domain have important effect on the effector function of the Fc domain, with minimal effect on antigen binding or half -life of the antibody (R. Jefferis, Biotechnol. Prog. 21 (2005), pp. 11-16).
• glycosylation of the variable domain may have an effect on the antigen binding activity of the antibody.
• Glycosylation in the variable domain may have a negative effect on antibody binding affinity, likely due to steric hindrance (Co, M.S., et al, Mol. Immunol. (1993) 30: 1361- 1367), or result in increased affinity for the antigen (Wallick, S.C., et al, Exp. Med. (1988) 168: 1099-1109; Wright, A., et al , EMBO J. (1991) 10:2717-2723).
• One aspect of the invention is directed to generating glycosylation site mutants in which the O- or N-linked glycosylation site of the binding protein has been mutated.
• One skilled in the art can generate such mutants using standard well-known technologies.
• Glycosylation site mutants that retain the biological activity, but have increased or decreased binding activity, are another object of the invention.
• the glycosylation of the anti-B7-H3 antibody or antigen binding portion of the invention is modified.
• an aglycoslated antibody can be made (i.e., the antibody lacks glycosylation).
• Glycosylation can be altered to, for example, increase the affinity of the antibody for antigen.
• carbohydrate modifications can be accomplished by, for example, altering one or more sites of glycosylation within the antibody sequence.
• one or more amino acid substitutions can be made that result in elimination of one or more variable region glycosylation sites to thereby eliminate glycosylation at that site.
• Such aglycosylation may increase the affinity of the antibody for antigen.
• Such an approach is described in further detail in PCT Publication WO2003016466A2, and U.S. Pat. Nos. 5,714,350 and 6,350,861, each of which is incorporated herein by reference in its entirety.
• a modified anti-B7-H3 antibody of the invention can be made that has an altered type of glycosylation, such as a hypofucosylated antibody having reduced amounts of fucosyl residues or an antibody having increased bisecting GlcNAc structures.
• altered glycosylation patterns have been demonstrated to increase the ADCC ability of antibodies.
• carbohydrate modifications can be accomplished by, for example, expressing the antibody in a host cell with altered glycosylation machinery. Cells with altered glycosylation machinery have been described in the art and can be used as host cells in which to express recombinant antibodies of the invention to thereby produce an antibody with altered glycosylation. See, for example, Shields, R. L. et al. (2002) /. Biol.
• Protein glycosylation depends on the amino acid sequence of the protein of interest, as well as the host cell in which the protein is expressed. Different organisms may produce different glycosylation enzymes ⁇ e.g., glycosyl transferases and glycosidases), and have different substrates (nucleotide sugars) available. Due to such factors, protein glycosylation pattern, and composition of glycosyl residues, may differ depending on the host system in which the particular protein is expressed. Glycosyl residues useful in the invention may include, but are not limited to, glucose, galactose, mannose, fucose, n-acetylglucosamine and sialic acid.
• the glycosylated binding protein comprises glycosyl residues such that the glycosylation pattern is human.
• Differing protein glycosylation may result in differing protein characteristics.
• the efficacy of a therapeutic protein produced in a microorganism host such as yeast, and
• glycosylated utilizing the yeast endogenous pathway may be reduced compared to that of the same protein expressed in a mammalian cell, such as a CHO cell line.
• Such glycoproteins may also be immunogenic in humans and show reduced half-life in vivo after administration.
• Specific receptors in humans and other animals may recognize specific glycosyl residues and promote the rapid clearance of the protein from the bloodstream.
• Other adverse effects may include changes in protein folding, solubility, susceptibility to proteases, trafficking, transport, compartmentalization, secretion, recognition by other proteins or factors, antigenicity, or allergenicity. Accordingly, a practitioner may prefer a therapeutic protein with a specific composition and pattern of glycosylation, for example glycosylation composition and pattern identical, or at least similar, to that produced in human cells or in the species-specific cells of the intended subject animal.
• glycosylated proteins different from that of a host cell may be achieved by genetically modifying the host cell to express heterologous glycosylation enzymes. Using recombinant techniques, a practitioner may generate antibodies or antigen binding portions thereof exhibiting human protein glycosylation. For example, yeast strains have been genetically modified to express non-naturally occurring glycosylation enzymes such that glycosylated proteins
• yeast strains exhibit protein glycosylation identical to that of animal cells, especially human cells (U.S. patent Publication Nos. 20040018590 and 20020137134 and PCT publication WO2005100584 A2).
• Antibodies may be produced by any of a number of techniques. For example, expression from host cells, wherein expression vector(s) encoding the heavy and light chains is (are) transfected into a host cell by standard techniques.
• transfection are intended to encompass a wide variety of techniques commonly used for the introduction of exogenous DNA into a prokaryotic or eukaryotic host cell, e.g. , electroporation, calcium-phosphate precipitation, DEAE- dextran transfection and the like.
• Preferred mammalian host cells for expressing the recombinant antibodies of the invention include Chinese Hamster Ovary (CHO cells) (including dhfr- CHO cells, described in Urlaub and Chasin, (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220, used with a DHFR selectable marker, e.g., as described in RJ. Kaufman and P.A. Sharp (1982) Mol. Biol. 159:601-621), NS0 myeloma cells, COS cells and SP2 cells.
• Chinese Hamster Ovary CHO cells
• dhfr- CHO cells described in Urlaub and Chasin, (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220, used with a DHFR selectable marker, e.g., as described in RJ. Kaufman and P.A. Sharp (1982) Mol. Biol. 159:601-621
• NS0 myeloma cells
• the antibodies When recombinant expression vectors encoding antibody genes are introduced into mammalian host cells, the antibodies are produced by culturing the host cells for a period of time sufficient to allow for expression of the antibody in the host cells or, more preferably, secretion of the antibody into the culture medium in which the host cells are grown. Antibodies can be recovered from the culture medium using standard protein purification methods.
• Host cells can also be used to produce functional antibody fragments, such as Fab fragments or scFv molecules. It will be understood that variations on the above procedure are within the scope of the invention. For example, it may be desirable to transfect a host cell with DNA encoding functional fragments of either the light chain and/or the heavy chain of an antibody of this invention. Recombinant DNA technology may also be used to remove some, or all, of the DNA encoding either or both of the light and heavy chains that is not necessary for binding to the antigens of interest. The molecules expressed from such truncated DNA molecules are also encompassed by the antibodies of the invention.
• bifunctional antibodies may be produced in which one heavy and one light chain are an antibody of the invention and the other heavy and light chain are specific for an antigen other than the antigens of interest by crosslinking an antibody of the invention to a second antibody by standard chemical crosslinking methods.
• a recombinant expression vector encoding both the antibody heavy chain and the antibody light chain is introduced into dhfr- CHO cells by calcium phosphate-mediated transfection.
• the antibody heavy and light chain genes are each operatively linked to CMV enhancer/ AdMLP promoter regulatory elements to drive high levels of transcription of the genes.
• the recombinant expression vector also carries a DHFR gene, which allows for selection of CHO cells that have been transfected with the vector using methotrexate selection/amplification.
• the selected transformant host cells are cultured to allow for expression of the antibody heavy and light chains and intact antibody is recovered from the culture medium.
• Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select for transformants, culture the host cells and recover the antibody from the culture medium.
• the invention provides a method of synthesizing a recombinant antibody of the invention by culturing a host cell in a suitable culture medium until a recombinant antibody is synthesized.
• Recombinant antibodies of the invention may be produced using nucleic acid molecules corresponding to the amino acid sequences disclosed herein The method can further comprise isolating the recombinant antibody from the culture medium.
• the N- and C-termini of antibody polypeptide chains of the present invention may differ from the expected sequence due to commonly observed post-translational modifications. For example, C- terminal lysine residues are often missing from antibody heavy chains. Dick et al. (2008) Biotechnol. Bioeng. 100:1132. N-terminal glutamine residues, and to a lesser extent glutamate residues, are frequently converted to pyroglutamate residues on both light and heavy chains of therapeutic antibodies. Dick et al. (2007) Biotechnol. Bioeng. 97:544; Liu et al. (2011) JBC 28611211; Liu et al. (2011) J. Biol. Chem. 286:11211. III. Anti-B7-H3 Antibody Drug Conjugates (ADCs)
• Anti-B7-H3 antibodies described herein may be conjugated to a drug moiety to form an anti- B7-H3 Antibody Drug Conjugate (ADC).
• ADCs Antibody-drug conjugates
• ADCs may increase the therapeutic efficacy of antibodies in treating disease, e.g., cancer, due to the ability of the ADC to selectively deliver one or more drug moiety(s) to target tissues, such as a tumor-associated antigen, e.g. , B7-H3 expressing tumors.
• the invention provides anti-B7-H3 ADCs for therapeutic use, e.g. , treatment of cancer.
• Anti-B7-H3 ADCs of the invention comprise an anti-B7-H3 antibody, i.e. , an antibody that specifically binds to B7-H3, linked to one or more drug moieties.
• the specificity of the ADC is defined by the specificity of the antibody, i.e., anti-B7-H3.
• an anti-B7-H3 antibody is linked to one or more cytotoxic drug(s) which is delivered internally to a transformed cancer cell expressing B7-H3. Examples of drugs that may be used in the anti-B7-H3 ADC of the invention are provided below, as are linkers that may be used to conjugate the antibody and the one or more drug(s).
• the terms “drug,” “agent,” and “drug moiety” are used interchangeably herein.
• the terms “linked” and “conjugated” are also used interchangeably herein and indicate that the antibody and moiety are covalently linked.
• the ADC has the following formula (formula I) wherein Ab is the antibody, e.g., anti-B7-H3 antibody huAbl3vl, huAb3v2.5, or huAb3v2.6, and (L) is a linker, (D) is a drug, and LK represents a covalent linkage linking linker L to antibody Ab; and m is an integer ranging from 1 to 20.
• D is a drug moiety having, for example, cytostatic, cytotoxic, or otherwise therapeutic activity against a target cell, e.g., a cell expressing B7-H3.
• Ab is the antibody, e.g., anti-B7-H3 antibody huAbl3vl, huAb3v2.5, or huAb3v2.6
• L is a linker
• D is a drug
• LK represents a covalent linkage linking linker L to antibody Ab
• m is an integer ranging from 1 to 20.
• D is
• m ranges from 1 to 8, 1 to 7, 1 to 6, 2 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, 1.5 to 8, 1.5 to 7, 1.5 to 6, 1.5 to 5, 1.5 to 4, 2 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2,or 2 to 4.
• the DAR of an ADC is equivalent to the "m" referred to in Formula I.
• the ADC has a formula of Ab- (LK-L-D) m , wherein Ab is an anti-B7-H3 antibody, e.g.huAbl3vl, huAb3v2.5, or huAb3v2.6, L is a linker, D is a drug, e.g., a Bcl-xL inhibitor or an auristatin such as MMAF or MMAE, and m is 2 to 4 (equivalent to a DAR of 2-4). Additional details regarding drugs (D of Formula I) and linkers (L of Formula I) that may be used in the ADCs of the invention, as well as alternative ADC structures, are described below. III. A. Anti-B7-H3 ADCs: Bcl-xL Inhibitors, Linkers, Synthons, and Methods of Making Same
• Dysregulated apoptotic pathways have also been implicated in the pathology of cancer.
• the implication that down-regulated apoptosis (and more particularly the Bcl-2 family of proteins) is involved in the onset of cancerous malignancy has revealed a novel way of targeting this still elusive disease.
• Research has shown, for example, the anti-apoptotic proteins, Bel 2 and Bcl-xL, are over- expressed in many cancer cell types. See, Zhang, 2002, Nature Reviews/Drug Discovery 1 : 101 ;
• aspects of the disclosure concern anti-hB7-H3 ADCs comprising an anti-hB7-H3 antibody conjugated to a drug via a linker, wherein the drug is a Bcl-xL inhibitor.
• the ADCs are compounds according to structural formula (I) below, or a pharmaceutically acceptable salt thereof, wherein Ab represents the anti-hB7-H3 antibody, D represents a Bcl-xL inhibitor drug (i.e., a compound of formula (Ila), (lib), (lie), or (lid) as shown below), L represents a linker, LK represents a covalent linkage linking the linker (L) to the anti-hB7-H3 antibody (Ab) and m represents the number of D-L-LK units linked to the antibody, which is an integer ranging from 1 to 20.
• m is 2, 3 or 4.
• m ranges from 1 to 8, 1 to 7, 1 to 6, 2 to 6, 1 to 5, 1 to 4, 2 to 4, 1 to 3, 1
• Bcl-xL inhibitors that may be used in the anti-B7-H3 ADC of the invention are provided below, as are linkers that may be used to conjugate the antibody and the one or more Bcl-xL inhibitor(s).
• linkers that may be used to conjugate the antibody and the one or more Bcl-xL inhibitor(s).
• the terms “linked” and “conjugated” are also used interchangeably herein and indicate that the antibody and moiety are covalently linked.
• One aspect of the instant disclosure concerns Bcl-xL inhibitors that have low cell
• the compounds are generally heterocyclic in nature and include one or more solubilizing groups that impart the compounds with high water solubility and low cell permeability.
• the solubilizing groups are generally groups that are capable of hydrogen bonding, forming dipole- dipole interactions, and/or that include a polyethylene glycol polymer containing from 1 to 30 units, one or more polyols, one or more salts, or one or more groups that are charged at physiological pH.
• the Bcl-xL inhibitors may be used as compounds or salts per se in the various methods described herein, or may be included as a component part of an ADC.
• Bcl-xL inhibitors that may be used in unconjugated form, or that may be included as part of an ADC include compounds according to structural formulae (Ila), (lib), (He), or (lid).
• # shown in structural formula (Ila), (lib), (lie), or (lid) below represents a point of attachment to a linker, which indicates that they are represented in a monoradical form.
• substituents independently selected from halo, hydroxy, nitro, lower alkyl, lower heteroalkyl, Q ⁇ aikoxy, amino, cyano and halomethyl;
• R 12 -Z 2b -, R'-Z 2b -, #-N(R 4 )-R 13 -Z 2b -, or #-R'-Z 2b - substituents are attached to Ar 2 at any Ar 2 atom capable of being substituted;
• Z 1 is selected from N, CH, C-halo, C-CH 3 and C-CN;
• Z and Z are each, independently from one another, selected from a bond, NR 6 , CR 6a R 6b , O, S, S(O), S(0) 2 , -NR 6 C(0)-,-NR 6a C(0)NR 6b -, and -NR 6 C(0)0-;
• R' is a alkylene, heteroalkylene, cycloalkylene, heterocyclene, aryl or heteroaryl
• solubilizing moiety containing a group selected from a polyol, a polyethylene glycol containing from 4 to 30 ethylene glycol units, a salt, and a group that is charged at physiological pH and combinations thereof, wherein #, where attached to R' , is attached to R' at any R' atom capable of being substituted;
• R 1 is selected from hydrogen, methyl, halo, halomethyl, ethyl, and cyano;
• R 2 is selected from hydrogen, methyl, halo, halomethyl and cyano
• R 3 is selected from hydrogen, methyl, ethyl, halomethyl and haloethyl;
• R 4 is selected from hydrogen, lower alkyl and lower heteroalkyl or is taken together with an atom of R 13 to form a cycloalkyl or heterocyclyl ring having between 3 and 7 ring atoms;
• R 6 , R 6 and R 6b are each, independent from one another, selected from hydrogen, optionally substituted lower alkyl, optionally substituted lower heteroalkyl, optionally substituted cycloalkyl and optionally substituted heterocyclyl, or are taken together with an atom from R 4 and an atom from R 13 to form a cycloalkyl or heterocyclyl ring having between 3 and 7 ring atoms;
• R lla and R nb are each, independently of one another, selected from hydrogen, halo, methyl, ethyl, halomethyl, hydroxyl, methoxy, CN, and SCH 3 ;
• R 12 is optionally R' or is selected from hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted heterocyclyl, and optionally substituted cycloalkyl;
• R 13 is selected from optionally substituted Ci_g alkylene, optionally substituted heteroalkylene, optionally substituted heterocyclene, and optionally substituted cycloalkylene;
• # represents the point of attachment to a linker L.
• Bcl-xL inhibitors that may be used in unconjugated form, or that may be included as part of an ADC include compounds according to structural formulae (Ila), (lib), (lie), or (lid):
• R 12 -Z 2b -, R' - Z 2b -, #-N(R 4 )-R 13 -Z 2b -, or #-R' -Z 2b - substituents are attached to Ar 2 at any Ar 2 atom capable of being substituted;
• Z 1 is selected from N, CH, C-halo, C-CH 3 and C-CN;
• Z and Z are each, independently from one another, selected from a bond, NR 6 , CR 6a R 6b , O, S, S(O), S(0) 2 , -NR 6 C(0)-,-NR 6a C(0)NR 6b -, and -NR 6 C(0)0-;
• R' is or , wherein #, where attached to R' , is attached to R' at any R' atom capable of being substituted;
• X' is selected at each occurrence from -N(R 10 )- , -N(R 10 )C(O)-, -N(R 10 )S(O) 2 -, -S(0) 2 N(R 10 )-, and -0-;
• n is selected from 0-3;
• R 10 is independently selected at each occurrence from hydrogen, lower alkyl, heterocycle, aminoalkyl, G-alkyl, and -(CH 2 ) 2 -0-(CH 2 ) 2 -0-(CH 2 ) 2 -NH 2 ;
• G at each occurrence is independently selected from a polyol, a polyethylene glycol with between 4 and 30 repeating units, a salt and a moiety that is charged at physiological pH;
• SP is independently selected at each occurrence from oxygen, -S(0) 2 N(H)-, -N(H)S(0) 2 -,
• m 2 is selected from 0-12;
• R 1 is selected from hydrogen, methyl, halo, halomethyl, ethyl, and cyano;
• R 2 is selected from hydrogen, methyl, halo, halomethyl and cyano
• R 3 is selected from hydrogen, methyl, ethyl, halomethyl and haloethyl;
• R 4 is selected from hydrogen, lower alkyl and lower heteroalkyl or is taken together with an atom of R 13 to form a cycloalkyl or heterocyclyl ring having between 3 and 7 ring atoms;
• R 6 , R 6 and R 6b are each, independent from one another, selected from hydrogen, optionally substituted lower alkyl, optionally substituted lower heteroalkyl, optionally substituted cycloalkyl and optionally substituted heterocyclyl, or are taken together with an atom from R 4 and an atom from R 13 to form a cycloalkyl or heterocyclyl ring having between 3 and 7 ring atoms;
• R lla and R nb are each, independently of one another, selected from hydrogen, halo, methyl, ethyl, halomethyl, hydroxyl, methoxy, CN, and SCH 3 ;
• R 12 is optionally R' or is selected from hydrogen, halo, cyano, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted heterocyclyl, and optionally substituted cycloalkyl;
• R 13 is selected from optionally substituted C 1 8 alkylene, optionally substituted heteroalkylene, optionally substituted heterocyclene, and optionally substituted cycloalkylene;
• # represents the point of attachment to a linker L.
• a Bcl-xL inhibitor of structural formulae (Ila)-(IId) is not a component of an ADC, # in formulae (Ila)-(IId) represents the point of attachment to a hydrogen atom.
• # in formulae (Ila)-(IId) represents the point of attachment to the linker.
• the ADC may comprise one or more Bcl-xL inhibitors, which may be the same or different, but are typically the same.
• R' is a C 2 -C 8 heteroalkylene substituted with one or more moieties containing a salt and/or a group that is charged at physiological pH.
• the salt may be selected, for example, from the salt of a carboxylate, a sulfonate, a phosphonate, and an ammonium ion.
• the salt may be the sodium or potassium salt of a carboxylate, sulfonate or phosphonate or the chloride salt of an ammonium ion.
• the group that is charged at physiological pH may be any group that is charged at a physiological pH, including, by way of example and not limitation, a zwitterionic group.
• a group that is a salt is a dipolar moiety such as, but not limited to, N-oxides of amines including certain heterocyclyls such as, but not limited to, pyridine and quinoline.
• the group that is charged at physiological pH is selected independently at each occurrence, from carboxylate, sulfonate, phosphonate, and amine.
• R' is a C 2 -C 8 heteroalkylene substituted with one or more moieties containing polyethylene glycol or a polyol such as a diol or a sugar moiety.
• R' may be substituted with groups in addition to a solubilizing moiety.
• R' may be substituted with one or more of the same or different alkyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or halo groups.
• R' is represented by the formula:
• X' is selected at each occurrence from -N(R 10 )- and -0-;
• n is selected from 1-3;
• R 10 is individually selected at each occurrence from hydrogen, alkyl, heterocycle, aminoalkyl, G-alkyl, heterocycle, and -(CH 2 ) 2 -0-(CH 2 ) 2 -0-(CH 2 ) 2 -NH 2 ;
• G at each occurrence is independently selected from a polyol, a polyethylene glycol with between 4 and 30 repeating unit (referred to herein as PEG4-30), a salt and a moiety that is charged at physiological pH;
• SP is independently selected at each occurrence from oxygen, sulfonamide, arylene, heterocyclene, and optionally substituted methylene; wherein methylene is optionally substituted with one or more of -NH(CH 2 ) 2 G, amine and carbonyl; and
• m 2 is selected from 0-6,
• R' wherein there is at least one substitutable nitrogen in R' that is attached to a linker or a hydrogen atom at a substitutable nitrogen atom of R'.
• R' is X' is selected at each occurrence from -N(R 10 )- , -N(R 10 )C(O)-, -N(R 10 )S(O) 2 -, -S(O) 2 N(R 10 )- : and -0-;
• n is selected from 0-3;
• R 10 is independently selected at each occurrence from hydrogen, alkyl, heterocycle, aminoalkyl, G-alkyl, heterocycle, and -(CH 2 ) 2 -0-(CH 2 ) 2 -0-(CH 2 ) 2 -NH 2 ;
• G at each occurrence is independently selected from a polyol, a polyethylene glycol with between 4 and 30 repeating units, a salt and a moiety that is charged at physiological pH;
• SP is independently selected at each occurrence from oxygen-S(0) 2 N(H)-, -N(H)S(0) 2 -, -N(H)C(0)-, -C(0)N(H) -, -N(H)- , arylene, heterocyclene, and optionally substituted methylene; wherein methylene is optionally substituted with one or more of -NH(CH 2 ) 2 G, amine, alkyl, and carbonyl;
• m 2 is selected from 0-12
• G at each occurrence is a salt or a moiety that is charged at physiological pH.
• G at each occurrence is a salt of a carboxylate, a sulfonate, a phosphonate, or ammonium.
• G at each occurrence is a moiety that is charged at physiological pH selected from the group consisting of carboxylate, a sulfonate, a phosphonate, and an amine.
• G at each occurrence is a moiety containing a polyethylene glycol with between 4 and 30 repeating units, or a polyol.
• the polyol is a sugar.
• R' of formula (Ila) or (lid) includes at least one substitutable nitrogen suitable for attachment to a linker.
• G is selected independently at each occurrence from:
• M is Na + , K + or Li + .
• M is hydrogen.
• G is S0 3 H. In certain embodiments, G is selected independently at each occurrence from:
• M is hydrogen or a positively charged counterion.
• M is hydrogen.
• G is S0 3 H.
• R' is selected from:
• the linker of the ADC is linked to the nitrogen atom of an available primary or secondary amine group.
• R' is selected from:
• the linker of the ADC is linked to the nitrogen atom of an available primary or secondary amine group.
• Ar 1 of formulae (Ila)-(IId) is se
• Ar 1 of formulae (Ila)-(IId) is optionally substituted with one or more substituents independently selected from halo,
• Ar 1 is
• Ar is optionally substituted with one or more substituents, wherein the R 12 -Z 2b -, R' -Z 2b -, #-N(R 4 )-R 13 -Z 2b -, or #-R' -Z 2b - substituents are attached to 2 at any Ar 2 atom capable of being substituted.
• R 12 -Z 2b -, R' -Z 2b -, #-N(R 4 )-R 13 -Z 2b -, or #-R' -Z 2b - substituents are attached to Ar 2 at any
• Ar 2 atom capable of being substituted.
• Ar 2 is selected from: , , and ; and is optionally substituted with one or more substituents, wherein the R 12 -Z 2b -, R' -Z 2b -, #-N(R 4 )-R 13 -Z 2b -, or #-R' -Z 2b - substituents are attached to Ar 2 at any Ar 2 atom capable of being substituted.
• Ar 2 is substituted with one or more solubilizing group.
• the each solubilizing group is, independently of the others, selected from a moiety containing a polyol, a polyethylene glycol with between 4 and 30 repeating units, a salt, or a moiety that is charged at physiological pH.
• Z 1 of formulae (Ila)-(IId) is N.
• Z 2 of formulae (Ila)-(IId) is O. In certain embodiments, Z 2 of formulae (Ila)-(IId) is CR 6 R 6b . In certain embodiments, Z 2 of formulae (Ila)-(IId) is S. In certain embodiments, Z 2 of formulae (Ila)-(IId) is -NR 6 C(0)-. In particular embodiments, R 6 is hydrogen.
• Z 2b of formulae (Ila)-(IId) is O. In certain embodiments, Z 2b of formulae (Ila)-(IId) is NH or CH 2 .
• R 1 of formulae (Ila)-(IId) is selected from methyl and chloro.
• R 2 of formulae (Ila)-(IId) is selected from hydrogen and methyl. In particular embodiments, R 2 is hydrogen.
• the Bcl-xL inhibitor is a compound of formula (Ila). In certain embodiments in which the Bcl-xL inhibitor is a compound of formula (Ila), the compound has the structural formul
• Ar 1 , Ar 2 , Z 1 , Z 2a , Z 2b , R 1 , R 2 , R lla , R nb , R 12 ' G and # are defined as above;
• Y is optionally substituted Q-Cg alkylene
• r is 0 or 1 ;
• s is 1, 2 or 3.
• the Bcl-xL inhibitor is a compound of formula (Ila. l)
• r is 0 and s is 1.
• the Bcl-xL inhibitor is a compound of formula (Ila. l)
• r is 0 and s is 2.
• the Bcl-xL inhibitor is a compound of formula (Ila. l)
• r is 1 and s is 2.
• Z 2 is selected from O, NH, CH 2 and S. In particular embodiments, Z 2 is O. In certain embodiments, Z 2 of formula (Ila.l) is -CR 6 R 6b -. In certain embodiments, Z 2 of formula (Ila. l) is CH 2 . In certain embodiments, Z of formula (Ila. l) is S . In certain embodiments, Z of formula (Ila.l) is
• Y is selected from ethylene, propylene and butylene. In particular embodiments, Y is selected from ethylene and propylene.
• G is OM . In particular embodiments, G is S0 3 H.
• Z 2b -R 12 is selected from H, F and CN. In particular embodiments, Z 2b -R 12 is H.
• the oxygen can serve as the point of attachment to a linking group (See Section 4.4.1.1).
• the Bcl-xL inhibitor is a compound of formula (Ila. l)
• a compound of formula (Ila.l) may be converted into the compound of formula IIa.1.1, wherein n is selected from 1-3:
• the compound of formula IIa.1.1 can be converted into a compound of formula Ila.l.2, wherein L represents a linker and LK represents a linkage formed between a reactive function .
• the Bcl-xL inhibitor is a compound of formula (Ila)
• the compound has the structural formula (Ila.2)
• Ar 1 , Ar 2 , Z 1 , Z 2a , Z 2b , R 1 , R 2 , R lla , R nb , R 12 and # are defined as above;
• U is selected from N, O and CH with the proviso that when U is O, then V and R 21 are absent;
• R 20 is selected from H and C -C 4 alkyl
• R 21a and R 21b are each, independently from one another, absent or selected from H, Q-C4 alkyl and G, where G is selected from a polyol, PEG4-30, a salt and a moiety that is charged at physiological pH;
• V and V b are each, independently from one another, absent or selected from a bond, and an optionally substituted alkylene;
• R 20 is selected from H and Q-C4 alkyl
• s is 1 , 2 or 3.
• s is 2.
• Z 2 is selected from O, NH, CH 2 and S. In particular embodiments, Z 2 is O. In certain embodiments, Z 2 of formula (IIa.2) is CR 6 R 6b . In certain embodiments, Z 2 of formula (IIa.2) is CH 2 . In certain embodiments, Z 2 of formula (IIa.2) is S. In certain embodiments, Z 2 of formula (IIa.2) is
• U is selected from N and O. In particular embodiments, U is O.
• V is a bond
• R 21 is a Q-C4 alkyl group
• V b is selected from methylene and ethylene and R 21b is G.
• V is a bond
• R 21 is a methyl group
• V b is selected from methylene and ethylene and R 21b is G.
• V is selected from methylene and ethylene
• R 21 is G
• V b is selected from methylene and ethylene and R 21b is G.
• V is ethylene
• R 21 is G
• V b is selected from methylene and ethylene and R 21b is G.
• G is wherein M is hydrog
• G is .
• G is S0 3 H.
• R 20 is selected from hydrogen and a methyl group.
• Ar 2 is
• R 12 -Z 2b - substituent is attached to Ar 2 at any Ar 2 atom capable of being substituted.
• Ar 2 is wherein the R 12 -Z 2b - substituent is attached to Ar 2 at any Ar 2 atom capable of being substituted.
• Z 2b -R 12 is selected from H, F and CN. In particular embodiments, Z 2b -R 12 is H.
• Ar 1 is in particular embodiments in which the Bcl-xL inhibitor is a compound of formula (IIa.2), Ar 2 is , wherein the R 12 -Z 2b - substituent is attached to Ar 2 at any Ar 2 atom capable of being substituted.
• the Bcl-xL inhibitor is a compound of formula (Ila)
• the compound has the structural formula (IIa.3)
• Ar 1 , Ar 2 , Z 1 , Z 2a , Z 2b , R 1 , R 2 , R lla , R nb , R 12 and # are defined as above;
• R b is selected from H, Q-C4 alkyl and J b -G or is optionally taken together with an atom of T to form a ring having between 3 and 7 atoms;
• J and J b are each, independently from one another, selected from optionally substituted Q-Cg alkylene and optionally substituted phenylene;
• T is selected from optionally substituted C C 8 alkylene, CH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 , CH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 OCH 2 and a polyethylene glycol containing from 4 to 10 ethylene glycol units;
• G is selected from a polyol, PEG4-30, a salt and a moiety that is charged at physiological pH;
• s is 1, 2 or 3.
• s is 1. In certain embodiments in which the Bcl-xL inhibitor is a compound of formula (IIa.3), s is 2.
• Z 2 is selected from O, CH 2 and S.
• Z 2 is O.
• Z 2 of formula (IIa.3) is CR 6 R 6b .
• Z 2 of formula (IIa.3) is CH 2 .
• Z 2 of formula (IIa.3) is S.
• Z 2 of formula (IIa.3) is -NR 6 C(0)- .
• the Bcl-xL inhibitor is a compound of formula (IIa.3)
• R b is J b -G, wherein J b is methylene or ethylene.
• T is ethylene.
• T is CH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 .
• T is a polyethylene glycol containing from 4 to 10 ethylene glycol units.
• the Bcl-xL inhibitor is a compound of formula (IIa.3)
• R b is taken together with an atom of T to form a ring having 4-6 ring atoms.
• the Bcl-xL inhibitor is a compound of formula (IIa.3)
• T is ethylene
• T is CH 2 CH 2 OCH 2 CH 2 OCH 2 CH 2 .
• G is wherein M is hydrog
• G is OM . i n particular embodiments, G is SO 3 H.
• R 20 is selected from hydrogen and a methyl group.
• Ar 2 is selected from
• the Bcl-xL inhibitor is a compound of formula (IIa.3)
• Ar is , wherein the substituent is attached to Ar 2 at any Ar 2 atom capable of being substituted.
• Z 2b -R 12 is selected from H, F and CN. In particular embodiments, Z 2b -R 12 is H.
• the Bcl-xL inhibitor is a com ound of formula IIa.
• the Bcl-xL inhibitor is a compound of formula (IIa.3)
• group is selected from:
• the Bcl-xL inhibitor is a compound of formula (lib). In certain embodiments in which the Bcl-xL inhibitor is a compound of formula (lib), the compound has the structural formula (Ilb.l),
• Ar 1 , Ar 2 , Z 1 , Z 2a , Z 2b , R 1 , R 2 , R 4 , R lla , R nb and # are defined as above;
• Y is optionally substituted Q-Cg alkylene
• G is selected from a polyol, PEG4-30, a salt and a moiety that is charged at physiological pH; r is 0 or 1 ; and
• s is 1, 2 or 3.
• the Bcl-xL inhibitor is a compound of formula (Ilb.l)
• s is 1. In certain embodiments in which the Bcl-xL inhibitor is a compound of formula (Ilb.l), s is 2. In certain embodiments in which the Bcl-xL inhibitor is a compound of formula (Ilb. l), s is 3.
• Z 2 is selected from O, CH 2 , NH and S. In particular embodiments, Z 2 is O. In certain embodiments, Z 2 of formula (Ilb. l) is CR 6 R 6b . In certain embodiments, Z 2 of formula (Ilb. l) is CH 2 . In certain embodiments, Z 2 of formula (Ilb.l) is S. In certain embodiments, Z 2 of formula (Ilb.l) is - NR 6 C(0)-. In certain embodiments in which the Bcl-xL inhibitor is a compound of formula (Ilb.l), Z is selected from O, CH 2 , NH, NCH 3 and S. In particular embodiments, Z 2b is O. In particular embodiments, Z 2b is NH. In particular embodiments, Z 2b is NCH 3 .
• Bcl-xL inhibitor is a compound of formula (Ilb.l)
• Y is ethylene and r is 0.
• Bcl-xL inhibitor is a compound of formula (Ilb.l)
• Y is ethylene and r is 1.
• R 4 is H or methyl. In particular embodiments, R 4 is methyl. In other embodiments, R 4 is H.
• R 4 is taken together with an atom of Y to form a ring having 4-6 ring atoms.
• the ring is a cyclobutane ring.
• the ring is a piperazine ring.
• the ring is a morpholine ring.
• M is hydrogen or a
• G is OM . i n other embodiments, G is S0 3 H. In particular embodiments, G is NH 2 . In other embodiments, G is P0 3 H 2 . In particular embodiments, G is NH 2 . In particular embodiments, G is C(0)OH. In particular embodiments, G is polyol.
• Ar 2 is , wherein the G-(CH 2 ) S -Z 2b - substituent is attached to Ar 2 at any Ar 2 atom capable of being substituted.
• the Bcl-xL inhibitor is a compound of formula (Ilb. l)
• Ar is selected from
• G-(CH 2 ) S -Z 2b - substituent is attached to Ar 2 at any Ar 2 atom capable of being substituted.
• the group is selected from:
• the Bcl-xL inhibitor is a compound of formula (Ilb.l)
• the Bcl-xL inhibitor is a compound of formula (Ilb.l)
• the Bcl-xL inhibitor is a compound of formula (lie). In certain embodiments in which the Bcl-xL inhibitor is a compound of formula (lie), the compound has the structural formula (IIc. l)
• Ar 1 , Ar 2 , Z 1 , Z 2a , Z 2b , R 1 , R 2 , R 4 , R lla ' R nb and # are defined as above;
• Y is optionally substituted Q-Cg alkylene
• Y b is optionally substituted Q-Cg alkylene
• R 23 is selected from H and C -C 4 alkyl
• G is selected from a polyol, PEG4-30, a salt and a moiety that is charged at physiological pH;
• Z is selected from O, CH 2 , NH and S.
• Z 2 is O.
• Z 2 of formula (IIc.l) is CR 6 R 6b .
• Z 2 of formula (IIc. l) is S.
• Z 2a of formula (IIc. l) is -NR 6 C(0)-.
• Z 2b is selected from O, CH 2 , NH, NCH 3 and S.
• Z 2b is O.
• Z 2b is NH.
• Z 2b is NCH 3 .
• Z 2b is a bond.
• Y is methylene or ethylene.
• Y is methylene, ethylene, or propylene.
• Z 2b is NR 6 , where R 6 is defined as above.
• R 6 is taken together with an atom from Y to form a cycloalkyl or heterocyclyl ring having between 3 and 7 ring atoms.
• the ring has 5 atoms.
• Y is ethylene
• Y is methylene
• Y is propylene
• R 4 is H or methyl. In particular embodiments, R 4 is H.
• Y b is ethylene or propylene. In particular embodiments, Y b is ethylene.
• R 23 is methyl
• R 23 is
• M is hydrogen or a
• G is OM . i n particular embodiments, G isS0 3 H.
• Ar is selected from
• the Bcl-xL inhibitor is a compound of formula
• Ar 2 is selected from
• #-N(R 4 )-Y -Z 2b - substituent is attached to Ar 2 at any Ar 2 atom capable of being substituted.
• Ar 2 is the #-N(R 4 )-Y -Z 2b - substituent is attached to Ar 2 at any Ar 2 atom capable g substituted.
• the G is a compound of formula (IIc. l)
• group is selected from:
• the Bcl-xL inhibitor is a compound of formula (IIc.l)
• group is selected from:
• the Bcl-xL inhibitor is a compound of formula (lie)
• the compound has the structural formula (IIc.2)
• Ar 1 , Ar 2 , Z 1 , Z 2a , Z 2b , R 1 , R 2 , R 4 , R lla ' R nb and # are defined as above;
• Y is optionally substituted Q-Cg alkylene
• Y b is optionally substituted Q-Cg alkylene
• Y c is optionally substituted Q-Cg alkylene

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Immunology (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Cell Biology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Peptides Or Proteins (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Plural Heterocyclic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicinal Preparation (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)

Priority Applications (31)

Applications Claiming Priority (4)

Publications (2)

Family

ID=59153289

Family Applications (1)

Country Status (35)

Cited By (24)

Families Citing this family (25)

Citations (63)

Family Cites Families (201)